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Foreword
A Picture of Health 2005 is the third in the series of publications
that describe some of the latest advances in health research 
by Irish researchers funded by the HRB. The broad spectrum 
of innovative research included in this year’s report reflects the increased support 
from the Department of Health and Children for health research and highlights
government recognition of the fact that today’s health research is tomorrow’s health
service. It also reinforces our national commitment to contribute to the global efforts 
to combat disease and improve equality and equity of care in our own health system.
While the social and economic impacts of effective health research can take time 
to manifest, a growing evidence base shows that it reaps great rewards; improved
healthcare, more effective treatment, preventative approaches to health issues 
and greater efficiency through new technologies. Such research also contributes
significantly to our national knowledge base as we move towards a knowledge-
based economy and society, and raises the profile of Irish health research among 
the international research community. 
In addition to enabling our best researchers to tackle national and international 
health challenges such as cancer, diabetes and heart disease, funding provided 
by the HRB also helps to build research capacity within the public health system 
by providing training for postgraduate students, and developing the research careers
of health professionals and young investigators through our various fellowship
schemes. The HRB greatly values the ongoing support of the public in our mission 
to improve health through research and information. We hope you enjoy reading 
A Picture of Health 2005.
Professor Desmond Fitzgerald
Chairman of the Health Research Board
The heart of the matter:
Cardiovascular health and disease
Blood clot? The answer could be NO! 2
The dietary supplement that can unblock arteries 2
Clot-busting science on a platelet 3
Cancer, clots and cardiovascular connections 4
Calcium is not just for bones 4
Are you feeling the pressure? 5
Eve and ecstasy, and what they can do to you 5
An on/off signal that controls blood vessel growth 6
Population health:
Society and people
Disadvantage is bad for your health 8
How active were you today? 9
Keep taking the tablets 9
Door to needle in 30 minutes? 10
Childhood cystic fibrosis – fathers also count 10
What to expect from a medical geneticist 11
Neuroscience: 
Brain matters
The genetics of ADHD 14
Time to pay attention 15
Destroy a protein, create a disease 15
Interfering interferon – the cure that feels worse than the disease 16
Break a protein, make a memory 16
Why cannabis is bad for young brains 17
Transports of delight? 17
Genes and autism 18
Diabetes:
Understanding a common condition
Coping better with diabetes 20
A nutrient that makes you make insulin 20
When blood vessels are damaged 21
Protecting cells from the ravages of diabetes 21
When your kidney becomes fibrous and fails 22
A gremlin in the kidney works 22
Cancer:
Tackling the big C
New screening tests for colon cancer 26
Cancer, commuting and quality of life 27
Genes, drugs and cancers 27
Keeping cancer at bay after surgery 28
How cells control their self-destructive tendencies 28
Software – for a better fitting drug 29
Chernobyl, radiation and thyroid cancer 30
CONTENTS
Immune affairs:
The battle rages
Viruses and you – it’s an arms race! 32
Getting back to normal after inflammation 32
Finding a system that controls lung inflammation 33
Parasites, hygiene and allergy 33
How an infection can trigger an asthma attack 34
The white blood cell that can restrict your breathing 34
Liver stem cells – and their many career options 35
The waste product that can do some good? 36
Infections, microbes and gut feelings
Probiotics and gut reactions 38
The key to infant meningitis? 39
How to avoid cancer of the oesophagus 39
How mimics can turn your body against you 40
Filming bugs – and why they’re so resilient 40
Filming bacteria – what makes them stick? 41
Health services:
From the cradle to the grave
Cultural diversity and maternity services 44
How to divide the health funding pie 44
A rational way to plan health services 45
The new face of after-hours GP care 45
I spy with my X-ray image 46
Death, dying and dementia 46
Human disease:
Confronting the causes 
Stopping the push of premature labour 48
Understanding pre-eclampsia – our constricted knowledge 48
Arthritis and a two-faced hormone 49
Could calcium-control drugs alleviate muscular dystrophy? 49
A more humane way to test toxins 50
Live action replay – for pathologists! 50
A new way to tackle psoriasis 51
Ironing out the problems of haemachromatosis 51
IV
MOST TYPES OF
CARDIOVASCULAR
DISEASE ARE
PREVENTABLE...
MOST TYPES OF
CARDIOVASCULAR
DISEASE ARE
PREVENTABLE...
The heart of the matter:
Cardiovascular health
and disease
“Most types of cardiovascular
disease are preventable.”
Source: Public Health Report November 2004; HSE Midland Area.
2Blood clot? 
The answer
could be NO!
Nitric oxide can stop blood
platelets sticking, scientists
at the Royal College of
Surgeons have discovered
Nitric oxide (chemical symbol: NO) is 
a small molecule that plays many roles
in regulating blood flow. Consequently,
it is an important target for many drugs
– Viagra, for instance, targets NO as 
a way of improving blood flow to a
certain part of the male anatomy, 
and angina drugs exploit NO’s ability 
to increase blood flow, in this case to 
a heart struggling because of a 
blocked artery. 
Angina can develop when a blood clot
forms in an artery and blocks the flow
to the heart. Scientists still don’t fully
understand how clots form, but it is
known that small blood cells called
platelets are important. Platelets
normally have a silky, disc-like
appearance, but when they sense
damage, they dramatically change their
appearance and become ‘sticky’, and
capable of forming a clot. Dr Niamh
Moran and post-doctoral researcher
Sarah O’Neill, at the clinical
pharmacology department of the 
Royal College of Surgeons in Ireland,
are studying platelets in the test tube.
They have discovered that there is a
biochemical ‘switch’ that controls this
change from silky to sticky. Crucially,
they have also discovered that NO 
can trip this switch, restoring sticky
platelets to their normal silky state. 
This is an important finding, and there
has been considerable interest in the
Irish study. The biochemical switch 
is probably not the only way that NO
regulates blood flow and blood clotting,
but it may explain why NO is useful 
in treating angina.
The dietary
supplement that
can unblock
arteries
Feeding mice a supplement
of conjugated linoleic acid
cleared the plaques from their
blocked arteries, a UCD
study discovered
There are currently no drugs that can
effectively clear blocked arteries. But
one day a simple dietary supplement
may do the trick: scientists at UCD’s
Conway Institute have now proven 
that conjugated linoleic acid (CLA), 
a naturally occurring fat-like substance
found in red meat and dairy products,
can clear the plaques from blocked
arteries. This holds out tremendous
promise, as atherosclerosis is the main
cause of heart disease and stroke, 
and accounts for 50% of deaths in
western societies.   
There is already considerable scientific
and medical interest in CLA’s potential
to treat cancer, diabetes and
inflammation. Now, Dr Orina Belton 
and PhD student Sinead Toomey, 
have shown that, if mice with
atherosclerosis take a CLA dietary
supplement (equivalent to 1% of their
food), the plaques in their arteries
disappear. The effect happens relatively
quickly – within as little as two weeks –
and the UCD scientists discovered 
the CLA works by ‘persuading’ the
macrophage cells that accumulate 
in the plaques to self-destruct.
There is however a cautionary note.
CLA comes in several chemical forms,
or isomers, with different atomic
arrangements, the two main ones being
termed 9-11 and 10-12. Each isomer
seems to have different metabolic
effects, and the picture is complicated
by contradictory findings. With insulin
sensitivity, for instance, some reports
suggest CLAs can increase insulin
concentrations, yet others found no
effect. The UCD supplement was 80%
9-11, and so Belton attributes the
positive effects they saw to this isomer.
Their results suggest we might one day
control atherosclerosis with a simple
‘nutraceutical’ dietary supplement, 
but in the meantime, the supplements
sold in health stores are usually an
unspecified mix, and people with
diabetes should use them with 
caution or under monitoring.
3 
Clot-busting
science on a
platelet 
Research at UCD is 
revealing what happens 
at the molecular level when
blood platelets are activated, 
and at the Royal College 
of Surgeons they can capture
these changes on a movie 
We don’t fully understand how blood
clots form, but we do know that small
blood cells called platelets play a key
role, and that the platelets must
become activated before a clot 
can form. However, there is a fine line
between having platelets ready to react
if you’re ever wounded, and
inappropriate platelet activity that 
might produce an unwanted clot 
(or thrombosis) in blood vessels, 
which could block the blood flow to
your heart or brain. People with high
blood cholesterol levels are prone to
developing diseased or damaged
arteries that can lead to blood clot
formation and so they are often
prescribed ‘statin’ drugs to lower
cholesterol levels. Patients prone 
to developing blood clots are often
prescribed clot-busting drugs 
(or anti- platelet agents) that can
prevent platelets from clumping
together into a clot. However, these 
can cause bleeding complications, 
so the search is on for new drugs with
fewer side-effects. For that, however,
we need a better understanding of 
how clots form.
Traditionally, platelet scientists study
platelet function in a test tube
environment, but at the Royal College
of Surgeons in Ireland, Dr Gerardene
Meade and Eimear Dunne (research
associate), set up a model system 
to study platelet function under
conditions that mimic blood flowing 
in blood vessels. This system
comprises a pump (or heart) to push
fresh blood through tubing and into 
a chamber that mimics a damaged
blood vessel surface, with 
a microscope and camera to image 
and record the flow at up to 30 frames
a second. In elegant experiments they
have shown that their system is a good
model of the real thing, and they are
now using it to study how platelets
become activated.  
Certain regions of a platelet receptor
protein called GP1b-IX-V are known to
be important in initiation of the clot
forming procedure, and Meade studied
a particular region and demonstrated its
functional importance under conditions
of blood flow.  In addition, it has been
shown that people often have different
versions of this protein (variable
regions) – something she plans to
investigate further.  Meanwhile, other
researchers are collaborating to use 
this system, including scientists
studying how infections can cause
blood clotting, and others investigating
how cancer cells spread by moving
through blood vessels.
Across the city at UCD's Conway
Institute, Dr Patricia Maguire (formerly
of the RCSI), and PhD student Martina
Foy, are studying the molecular events
that happen when platelets become
activated. They are interested in special
regions of the cell membrane where 
the structure seems to be different, 
and these areas seem to function as
meeting places – where proteins can
come and go and interact with other
proteins. Scientists call these putative
structures 'lipid rafts' and, using new
proteomic techniques to identify the
molecules present, the UCD team has
found over 150 proteins in the platelet
lipid rafts, many of them not previously
known in platelets. This suggests that
platelet activation is more complex 
than originally thought, and by way of
example, Maguire and Foy have found
that one of the new lipid proteins 
(RGS-19), interacts with another protein
(a chaperone, called 14-3-3), which can
also bind with the key receptor protein,
GP1b-IX-V. Maguire would now like 
to analyse lipid rafts in platelets from
people with different blood cholesterol
levels to see if some people have more
rafts, or different rafts, and if this 
can explain why people with high
cholesterol are more prone to
developing dangerous blood clots. 
Image caption: Scanning electron micrograph 
of blood corpuscles on clot
4Cancer, clots and
cardiovascular
connections
Gene studies at UCD
revealed that two genes
normally associated with
cancers also play a role 
in atherosclerosis
A blocked artery can kill. It can trigger 
a heart attack if it blocks blood flow to
the heart, or cause a stroke by blocking
blood flow to the brain. Blockages are
caused by the build up of plaques, 
but plaques are not just fatty deposits
of cholesterol: they usually become
coated with a layer of smooth muscle
cells, and acquire a blood supply, 
and thus have some similarities with
tumours. Scientists recently discovered
that plaques with a rich blood supply
are more likely to rupture and lead 
to clot formation.  
To explore what is happening, Dr Susan
Connolly, a clinician training in
cardiology, teamed up with scientists 
at UCD’s Conway Institute for a fishing
expedition…fishing, that is, to identify
what genes are active in the cells
around a plaque. Using DNA
microarrays to reveal what’s switched
on at any one time, they found that
some 600 genes are significantly more
active in stressed smooth muscle cells
than in healthy ones. Next, they
identified the types of genes as they
were switched on (those associated
with new blood supply formation, 
for instance), and this spotlighted 
two genes of interest. They found that
PTTG1 (pituitary tumour transforming
gene 1), already associated with certain
cancers, is activated in plaques, and
especially in ruptured plaques. And that
calvasculin, a gene associated with
aggressive metastasising cancers, 
is also switched on in plaques, where 
it possibly mobilises the muscle cells.
These intriguing connections between
cancer and cardiovascular disease are
another piece in the jigsaw as we piece
together what happens during disease.
Calcium is not
just for bones
Scientists at UCC have
discovered how calcium ions
act as important messengers
in immune cells and in the
muscle cells of blood vessels
Mention calcium and the body, 
and most people probably think of
bones.  But calcium ions (Ca2+) 
are also important messengers in your
cells, carrying in signals from outside
and helping control processes such 
as muscle contraction. To this end, cells
keep a store of calcium ions in special
reservoirs and, when the ions are
needed, special protein channels can
be opened to release them. These all-
important protein channels are called
ryanodine receptors, and one type,
ryanodine receptor type 1 (RyR1), 
is essential for controlling contractions
in your skeletal muscles. Here its
function is well understood, but the
same protein is also found in other
tissues including immune cells (the 
B-lymphocytes) and in the smooth
muscle cells of blood vessels (vascular
smooth muscle), and biologists at
UCC's Department of Biochemistry 
are investigating its role there.
Dr John Mackrill and Prof Tommie
McCarthy have discovered that 
when the RyR1 channels open in 
B-lymphocytes, the concentrations 
of various components inside the cell
change, which they believe has
implications for the immune system. 
In the vascular smooth muscle cells,
they found that opening the channels,
and releasing the calcium ions, reduces
the levels of the enzymes that
dismantle the blood vessel wall
(specifically, the matrix or 'mortar' 
that holds the cells together). This, 
they now believe, happens because 
the calcium ions can switch off the
genes that code for these enzymes.
This may explain how blood vessels
grow differently in certain diseases,
information which could be useful 
in developing new therapies for
cardiovascular problems and to stop
the blood flow to growing tumours.
5Are you feeling
the pressure?
At DCU, scientists are
discovering how high-blood
pressure can alter the 
very structure of your 
blood vessels
Every heartbeat pumps blood through
your vascular system, and as the blood
flows through it generates mechanical
forces that can profoundly affect the
structure and function of the blood
vessels. There is the frictional force 
(or shear stress) as the blood drags
against the endothelial cells lining the
inside of the vein or artery, and an
outward pushing or stretching force 
(the cyclic strain) generated by each
beat of the heart, which mostly affects
the vascular smooth muscle cells. 
Over time, and especially if a person
has high blood pressure or a blocked
artery, these physical forces can take
their toll on the blood vessels.
At DCU’s Vascular Health Research
Centre, scientists led by Prof Paul Cahill
are investigating how the cells in blood
vessels actually detect and respond 
to the mechanical forces involved. 
In one project, with PhD student David
Morrow, the researchers have proven
that subjecting vascular smooth muscle
cells to cyclic strain makes them
dysfunctional, a change that contributes
to the root cause of vascular disease.
They also discovered that this change
regulates the expression of a family 
of genes, the Notch genes, which are
normally active only during embryonic
development of the vessel, when they
are crucial to the growth of the blood
vessels. The DCU study suggests that,
if we could find a way to target the
Notch genes in the dysfunctional cells,
it might provide a new way to treat
cardiovascular disease.
In a separate study, research fellow 
Dr Philip Cummins is investigating how
the endothelial cells that line the blood
vessels can detect and then respond 
to the mechanical forces. Several
receptor proteins on the surface of the
cells are probably involved, including a
group called the regulatory G-proteins.
Cummins has now shown that two
regulatory G-proteins (Gα and 
Gβγ, from the inhibitory 
G-protein family), play different roles 
in detecting the mechanical signals. 
These enable the cells to respond to
the forces, and a better understanding
of these molecular mechanisms may
ultimately help us to develop new ways
to diagnose, treat and manage
cardiovascular disease.
Eve and ecstasy,
and what they
can do to you
Physiologists at the Royal
College of Surgeons have
discovered one of the ways 
in which amphetamines can
affect a person’s metabolism
Here’s what we know. Ecstasy, or
MDMA, to give the drug its scientific
acronym, can seriously alter a person’s
metabolism, raising their core body
temperature, for example, and setting
their heart racing. We also know that 
it can mimic two neuro-chemicals,
serotonin and dopamine. Now,
physiologists at the Royal College 
of Surgeons in Ireland have discovered
that ecstasy can mimic a third
neurochemical, noradrenaline, and they
believe this explains some of the drug’s
potentially lethal side-effects.
Prof Jim Docherty and Dr Sotiria Bexis
are studying not just MDMA, but also
three other related drugs: two
amphetamine derivatives – MDEA
(known in the parlance as Eve), and
MDA, which is produced in the body
when ecstasy is metabolised – along
with cathinone (the major constituent 
of Khat). By analysing the effects of 
the four drugs on lab rats, the scientists
have confirmed that all four significantly
affect the animals’ metabolism, altering
their heart ECG patterns (ecstasy and
its metabolite MDA produced the most
marked change), raising their core body
temperature (with MDA, again, in
particular causing the animals to
overheat), and increasing their blood
pressure (again, MDA was worst, 
while MDEA had no affect on blood
pressure). The scientists also
discovered that MDMA can mimic 
the neurotransmitter noradrenaline, 
and interact with a noradrenaline
receptor, called alpha-2, and they
believe this partly explains how ecstasy
can interfere with heart function and
body temperature. Their research also
revealed that much of the damage done
by ecstasy is probably caused by the
MDA produced in the body as the drug
is metabolised.
6An on/off signal
that controls
blood vessel
growth
Biochemists at the Royal
College of Surgeons have
pieced together one of the
mechanisms controlling the
growth of new blood vessels
There are times when new blood vessels
are a good thing – in a developing embryo,
for instance, or to heal a wound. But there
are also times when new blood vessels are
decidedly ‘a bad thing’, notably when they
are growing to supply a tumour, or an
already inflamed region. So there is
considerable scientific interest in
understanding the signals that switch 
this growth on and off. Angiogenesis 
is the name scientists give to blood vessel
growth, and the process happens when
endothelial cells lining an existing blood
vessel start to proliferate. There are
probably several mechanisms controlling
this, and at the Royal College of Surgeons
in Ireland, Dr Aideen Long and PhD
student Frances Lennon, are studying 
one of those mechanisms. 
They have discovered that hyaluronic acid,
found in the gel that surrounds and binds
the endothelial cells together, can dock
with a molecule called CD44 on the
surface of the cells. This, they have
discovered, sets off an important chain
reaction – leading to production of
vascular endothelial growth factor, that
activates the cycloxygenase-2 enzyme,
that produces prostacyclin… that
ultimately triggers the endothelial cells 
to proliferate. This valuable information
could one day lead to the development 
of new drugs to control the growth of
blood vessels and help treat inflammation
or starve cancers of their essential 
blood supply.
Winning entry in HRB’s Picture of Health image
competition. Image was taken by PhD student
Frances Lennon in RCSI.
Image caption: Activated endothelial cells stained 
for actin (green) and rab5 (red). Actin forms part of 
the cell skeleton while rab5 is a marker of endosomes 
(small portions of the cell membrane which cleave 
and internalise to form small vesicles which carry 
‘cargo’ into cells).
…SOCIAL,
ECONOMIC AND
MATERIAL
DISADVANTAGE
DAMAGE PEOPLE’S
HEALTH…SOCIAL,
ECONOMIC AND
MATERIAL
Population health:
Society and people
“…social, economic and
material disadvantage damage
people’s health.”
Source: ‘Disadvantage is bad for your health’,  Prof Cecily Kelleher (Public Health, UCD) 
8Disadvantage 
is bad for 
your health 
A major five-year study, that
is capturing a picture of the
nation’s health, reveals how
social, economic and material
disadvantage are damaging
people’s health
If you are well-off – if for example both
your parents had a third-level education
– then you are more likely to be in good
health. Conversely, if you are socially,
materially or economically
disadvantaged – if for example your
income is so low that you qualify for 
a medical card – then you are more
likely to rate your health as poor. 
That’s the message, in simple terms,
from a major five-year study of the
health status of Irish people.
Begun in 1999, and co-ordinated by
Prof Cecily Kelleher from UCD’s
department of Public Health Medicine 
& Epidemiology, the project involved a
large multi-disciplinary team from UCD
and NUI Galway.* They analysed
information from previous national
health and lifestyle surveys, and
undertook two sizeable new studies:
first, Lifeways, a five-year study across
three generations, involving children,
parents and grandparents; and second,
a detailed social comparison of two
communities. The aim was to assess
people’s current health status, and to
identify the social factors that affect
health status and thus what needs to
change if we are to improve people’s
health status.
The starting point for the Lifeways
project was when 1,124 Irish-born
pregnant women volunteered to join 
the study. Data on their pregnancy and
labour and the birth were collected from
the maternity hospitals, and the study
then grew to encompass the child and
the mother’s partner/spouse, and the
child’s grandparents – in all, over 2,000
adults across three generations. These
people supplied information on their
health, lifestyle and nutrition, and kept
records of GP and hospital visits; over
1,000 grandparents were also clinically
examined at home by a nurse.
The second, complementary study was
very different, in that it entailed detailed
interviews and focus group discussions
in two communities (one a suburban
community in a large city, and the other
a more rural community, and for
confidentiality codenamed Ballyeast
and Ballywest), along with interviews
and information from various
disadvantaged groups, such as
Travellers, a men’s social club, lone
parents, a domestic violence support
group, low-income women, and carers. 
The research confirmed that people
who are well-off enjoy better health
than those who are socially,
economically and materially
disadvantaged. The clearest indication
comes from those with a medical card,
itself a direct measure of income.
Education, and especially third-level
education, is also important: people
who have a third-level qualification are
more than twice as likely to say their
health is good or excellent; and a
young mother is seven times more
likely to enjoy good health if both her
parents had a tertiary education. As
might be expected, lifestyle factors
such as diet/nutrition, alcohol intake
and smoking are also important.
Smokers, for example, are nearly three
times as likely to say they suffer from
poor health as non-smokers. This ties
in with the information on income, as
generally smokers are also less well-off
than non-smokers. The same picture
emerged from a comparison of the
Ballyeast and Ballywest communities:
disadvantage can seriously damage
your health, and it involves factors as
complex as self-esteem, and as basic
as access to health care services.
The project team is now drafting policy
recommendations aimed at improving
people’s health status. Meanwhile, they
recommend that the Lifeways study,
which is a valuable baseline and a
snapshot of the country’s health status,
should continue until at least the
children reach school-going age. 
*At NUI Galway: Prof Andrew Murphy
(Department of General Practice), 
Dr Eamon O’Shea (Economics), 
Dr Margaret Barry (Health Promotion)
and Dr Michelle Millar (Political Science
& Sociology)
9How active were
you today?
It’s hard to design an
effective questionnaire that
gathers accurate data about
how active people are, 
but scientists at DCU 
have now done it
We all need at least 30 minutes of
moderately intense physical activity 
at least five times a week, and for
people with conditions such as
diabetes and heart disease, regular
physical activity is crucial to staying
healthy. To ascertain how much
physical activity a patient is getting,
healthcare staff use recall-type
questionnaires, typically asking
someone what they did in the previous
week. But the results are generally
inaccurate. That’s because, according
to Dr Catherine Woods, an exercise
scientist at DCU’s School of Health 
and Human Performance, the
questionnaires ask the wrong
questions, and ask them in the 
wrong way.
To design effective questionnaires, 
you need to understand how people
think and how they recall events, and
give them appropriate phrases and
prompts in the questions. Woods and
PhD student Niamh Martin employed
cognitive psychology techniques to
devise model questionnaires designed
to make recall easy and accurate. 
Their questionnaires incorporate a
calendar and descriptions of physical
and psychological reactions to activity,
all designed to help people remember
what they did on a particular day. 
They have now designed three
questionnaires tailored to specific age
groups (12-17 years old, 18-55, and
over-55), taking account of lifestyle, 
and including activities such as
housework which are often overlooked
by other questionnaires. 
Dr Martin is now using the new
questionnaires in a healthcare
intervention programme for the HSE
northern area, and copies of the
questionnaires are available from 
Dr Woods at DCU. 
Keep taking 
the tablets
One-third of people who 
are given drugs for high
blood pressure or high
cholesterol do not go beyond
their first prescription, 
a TCD study reveals
People with high blood pressure or high
cholesterol are more likely to develop
coronary heart disease. So, even if they
have no obvious symptoms, they are
usually prescribed drugs, such as one
of the statins now used to lower
cholesterol. But if someone has no
symptoms, they may not appreciate 
the need to take a drug, and if the drug
has unpleasant side-effects, they may
be tempted to stop taking it. To look at
patterns of drug use, Dr Kathleen
Bennett, a medical statistician at TCD’s
Centre for Health Sciences, and PhD
student Nicola Fitz-Simon analysed
prescription data from the General
Medical Services scheme for some
11,000 people claiming prescriptions
for hypertensive drugs, and 7,000
people claiming for statins.
They found that nearly one-third of
people stopped their prescription after
just one month of treatment – 32% 
of patients taking statins, and 37% 
of those taking hypertensive medication
cashed only one prescription.
Interestingly, younger and older patients
were more likely to stop than those who
were middle-aged. With several statins
to choose from, many patients start
with one type and, if they do not
respond well to it or experience
unpleasant side-effects, switch to
another. The researchers found that
two-thirds of those switching their
statin therapy did so in the first two
months. All of which suggests that 
GPs and consultants should give extra
support to patients in the first few
months of a therapy, to ensure that
those who need to take medication
keep taking the tablets.
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Door to needle
in 30 minutes?
Women are less likely 
to survive a heart attack 
than men, because their
symptoms are not recognised
in time, according to a 
TCD survey
Time is of the essence if you are having
a heart attack, and ideally, people need
to receive the essential clot-busting
thrombolysis injection within 30
minutes. Yet many people have not
even seen a doctor by that time, and
bad as the situation is for men, it is
considerably worse for women.
Numerous international studies report
that women are more likely to die
following a heart attack than men: one
US study found that women were three
times more likely to die within 30 days
of being hospitalised for a heart attack,
than men.
To assess the Irish situation, Dr Sharon
O’Donnell, a research fellow at TCD’s
School of Nursing, examined the 
pre-hospital experience and in-hospital
care of Irish men and women who had
a heart attack. She discovered that Irish
women do not see themselves as
potential heart attack victims, do not
recognise the early warning signs (often
brushing them off as minor ailments),
and take longer to call for help. Even
when they reached hospital, medical
staff took longer to recognise the
women’s condition. Result: while the
‘door to needle’ time for men in Ireland
is 52 minutes on average, for women 
it is 70 minutes, with many taking even
longer. Part of the problem, O’Donnell
says, is that women often have atypical
symptoms, such as tiredness and
nausea, and their condition is slow 
to develop, in contrast to the classical
male symptoms of sudden, acute chest
and arm pain.  She believes we need 
a major campaign to educate women,
their families and GPs, and A&E staff
about the problem. Meanwhile, if you
think you are having a heart attack, 
take an aspirin, and an ambulance
straight to hospital.
Childhood cystic
fibrosis – fathers
also count 
Health care teams should
involve the fathers as well as
the mothers of children with
cystic fibrosis, a UCC nurse
researcher recommends
Caring for a young child with cystic
fibrosis can put big demands on
parents. Most studies focus on the
mothers’ needs and perspectives,
however, and the fathers’ voices are
rarely heard. To redress this balance,
clinical nurse Claire Hayes, working
with Dr Eileen Savage at UCC’s School
of Nursing, interviewed the fathers 
of young children diagnosed with 
cystic fibrosis.
Caring for a chronically ill child is time-
consuming and, according to Hayes,
one parent will often give up work,
usually the mother, so that care teams
may unwittingly address mothers more
than fathers. The fathers interviewed
said their work commitments limited 
the time they could spend with their
child. Nevertheless, they were all
involved in the day-to-day care,
especially the chest physiotherapy.
Hayes found that, for fathers, an
important part of managing involved
getting information from the medical
team, searching for the latest research
news on the Web, and getting practical
advice from other parents in a similar
situation. Those interviewed revealed
that, though they might not often
discuss their child’s illness with others,
they were often upset by it. Their social
life could also be badly affected: some
were reluctant to leave their child with
others and consequently it was difficult
for them to have a night out together. 
Hayes recommends that health care
teams should actively include fathers
and should stress the need for parents
to have a trusted other person they 
can leave their child with. Care teams
should consider providing more
information for fathers, and offer 
them support, though more research 
is needed to clarify what support
structures are needed.
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What to expect
from a medical
geneticist
Parents need more
information and support
when preparing for a genetic
investigation, a University of
Ulster study recommends
Genetic investigations are unlike any
other medical appointment. Geneticists
might not listen to a child’s heart, 
for instance, but might do something
unexpected such as examining the
child’s feet, which can seem bizarre 
to parents who have exhausted the
usual round of medical tests. For some
parents, a genetic investigation may
provide an answer after months of
searching, even if that answer raises
concerns about guilt or blame. 
But other parents’ hopes are dashed 
if genetics cannot provide an answer.
Consequently, parents need to
understand fully what a genetic
investigation entails, and the power 
and limitations of genetic testing.
Community nurse Dr Owen Barr, 
a nursing researcher at the University 
of Ulster, interviewed 19 parents of
children who were being referred for
their first appointment with a medical
geneticist, and he surveyed some 200
health visitors in Northern Ireland. 
He found that most parents welcomed
the genetic investigation but were
poorly informed about it, and that
health visitors could not support them,
because they were not aware of the
referral. Dr Barr’s study has already 
led to changes in Northern Ireland: 
the Belfast service produced a new
information leaflet for parents, and its
letter of appointment now invites any
parent with questions to contact them
directly. But Barr says it would also
help if GPs and consultants appreciated
the special nature of genetic testing,
and informed health visitors of a
referral, so they could also support 
the family.
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CANNABIS CAUSES
YOUNG BRAIN
CELLS TO SELF-
DESTRUCT…..CAN
NABIS CAUSES
YOUNG BRAIN
CELLS TO SELF-
DESTRUCT…..
Neuroscience: 
Brain matters
“Cannabis causes young brain
cells to self-destruct…..”
Source: ‘Why cannabis is bad for young brains’, Dr Veronica Campbell (Physiology, TCD)
The genetics 
of ADHD
Scientists at TCD are winning
international recognition for
their work on ADHD, and here
we report on two studies that
have identified some of the
genes involved
Inattentive, distractible, impulsive,
hyperactive…the main symptoms of
attention deficit hyperactivity disorder
(ADHD), a behavioural condition that
affects 2-5% of school-aged children
worldwide. Thanks to research in
Ireland and elsewhere, it is now clear
that a child’s susceptibility to ADHD
depends on many genes, as well as
environmental factors. It’s also now
known that dopamine, a neuro-
transmitter used for signalling 
by nerve cells in the brain, is important:
block the dopamine transporter, and
thus alter dopamine levels in certain
regions of the brain, and you can
alleviate symptoms for up to 70% 
of ADHD children – which is precisely
how the drug methylphenidate, 
alias Ritalin, works.
TCD neuropsychiatric geneticist 
Dr Ziarih Hawi and colleagues have
now confirmed that the dopamine
transporter gene is associated with
susceptibility to ADHD, and crucially
this may determine how well a child
responds to medication. The team 
then identified another risk gene,
coding for one of the dopamine
receptors, called DRD5: in a major
international study across 14 countries,
co-ordinated by TCD, Dr Naomi Lowe
confirmed the importance of this gene
in ADHD. Researchers elsewhere 
had shown that a second dopamine
receptor, DRD4, was associated with
ADHD, and Dr Hawi’s team has now
confirmed this and, they believe,
located the problem to the gene’s
control region. 
Intriguingly, Dr Hawi’s team also
discovered that the effects of these risk
genes are more likely to come from the
child’s father than from their mother.
This suggests that a mechanism known
as ‘imprinting’ is important (some genes
are marked, depending on which parent
they are inherited from, to control their
activity), and in this way, the father’s
genes become more influential in 
the development of ADHD than 
the mother’s.
In addition to attention deficit and
hyperactivity, people with ADHD are
prone to cognitive problems, such as
difficulties in thinking and planning. 
Two TCD psychiatrists, Prof Michael Gill
and Dr Mark Bellgrove, wondered if this
separate phenomenon is caused by the
same genes that put people at risk of
ADHD. Gill and Bellgrove found that
people’s ability to sustain their attention
during repetitive tasks is indeed
affected by several genes that code 
for neurotransmitters, and suggests 
that the genes implicated in ADHD 
are also responsible for the cognitive
deficits, work that is helping us to
understand how genes affect the
development of the brain.
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What is ADHD?
Attention deficit hyperactivity
disorder (ADHD, or HADD) is a
neurobiological disability, frequently
characterised by inappropriate
degrees of inattention, impulsivity
and hyperactivity.
When left untreated, a child is 
at significant risk of developing
impaired learning ability, decreased
self esteem, social problems, family
difficulties and potential serious long
term affects. 
Between 5 - 10% of Irish children
are estimated to have ADHD.
Source: HADD family support group, May 2005
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Time to pay
attention
A study at TCD reveals that
kids with ADHD have a poor
sense of time, and suggests
that ‘time training’ might
improve their attention skills
Training with a metronome, and learning
simple exercises to a beat, might help 
a child who has attention deficit
hyperactivity disorder (ADHD) to
improve their sense of time, and
perhaps even their ability to maintain
attention. That is the suggestion from 
a study by research psychologist 
Dr Celine Mullins, working at TCD 
with Prof Ian Robertson and Prof
Michael Gill.
There are two main types of ADHD:
children whose problem is inattention
(the inattention subtype), and children
who, in addition, are also hyperactive
and impulsive (the combined subtype).
Both groups seem to perceive that time
runs fast, so that five minutes might 
feel to them more like 10. But is this
because they have trouble maintaining
attention, or is it something separate?
Time perception is subjective and
difficult to study, so Mullins devised
simple computer-based tests, such 
as asking children to reproduce a
sequence that lasted a set time, or to
say which of several events happened
first, and she gave these tests to
children with ADHD and to other
children. She found that ADHD children
have poor time perception, and that this
is not just because of their attention
difficulties. Studies elsewhere suggest
that a metronome can help children to
learn simple movements (e.g. clapping
and toe-tapping), and Mullins believes
such time training could help ADHD
children to improve their sense of time,
and perhaps even win some control
over their attention deficits and
impulsiveness. Similarly, giving children
time clues while they are engaged 
in a task could help them to 
remain focused.
Destroy a
protein, create 
a disease
Cell biologists at UCD 
believe that diseases such 
as multiple sclerosis and
Alzheimer’s develop because
brain cells start destroying 
a crucial protein
Alzheimer’s disease and multiple
sclerosis are very different disorders,
yet they have one thing in common:
both are associated with inflammation
in the brain.  Normally, inflammation 
is a good thing, part of the body’s
response to infection, with white blood
cells moving from the blood vessels
into the infected tissue where they can
attack the invading micro-organism.
And normally this movement is tightly
controlled, since inappropriate
inflammation can damage healthy
tissue and cause disease. Yet this is
precisely what seems to go wrong in
diseases such as Alzheimer’s and MS,
and at UCD’s Conway Institute, cell
biologists are trying to understand why.
Dr Paul Moynagh and PhD student
Bryan Griffin are interested in a protein
called IκBβ which normally helps
regulate inflammation by blocking 
the movement of white blood cells into
tissue. They culture brain cells in the
lab, and can simulate conditions in 
MS by exposing the cells to a signal
that triggers inflammation. When this
happens, they found that the IκBβ
protein disappears from the brain cells
for long periods. Significantly, this
absence may explain how white blood
cells can accumulate in the brains of
people with MS. Moynagh’s team 
has also discovered how the protein
disappears: first, it is made as normal;
then, in response to the inflammatory
signal, it is degraded; it is then remade,
but immediately modified by a process
called phosphorylation, which marks 
it out for degradation, and then finally
destroyed. The team is now looking at
ways of stabilising the protein to
prevent it being destroyed, work which
in the long-term could be of benefit 
in understanding several diseases.
16
Interfering
interferon – the
cure that feels
worse than the
disease
Research at TCD may have
identified a way to overcome
some of the awful side-
effects of the drug used 
to treat hepatitis C
Long-term hepatitis C infection can
leave you needing a liver transplant, 
so it’s important to treat the disease
early. Happily, there is one drug that will
cure the infection very effectively, called
interferon alpha. Unhappily, it causes
awful side-effects in some 70% of
patients, ranging from depression,
anxiety and memory loss, to manic/
paranoid psychoses and even suicidal
ideation. Some have likened it to
"having a finger inserted in your brain",
and many are tempted to stop taking
the drug before their six-month course
is up. Indeed, the side-effects are so
severe that people on interferon alpha
must undergo psychiatric assessment
and monitoring. Until now, not much
was known about interferon’s effects on
the brain. But Prof Shane O’Mara and
PhD student Briana Fahey at TCD’s
Institute of Neuroscience, and Dr Ann-
Marie O’Dwyer, a consultant
psychiatrist at St James’ Hospital, 
have now studied its effects on the
brains of rats and elucidated how it
affects behaviour, the brain and the
brain chemistry. Interferon is actually 
a natural substance, produced by our
immune system in response to
infection; but very high doses of
manufactured drug are needed to kill
the hepatitis C virus. 
The TCD scientists discovered that at
high doses the drug reduces the brain’s
electrical activity, increases the levels 
of stress hormones, and reduces the
levels of an important brain chemical,
brain-derived neurotrophic factor. 
Rats given the drug also appeared
anxious and depressive-like.
Significantly, many of the side-effects
disappeared if the rats were given 
the anti-depressant, Prozac, and the
side-effects were further reduced if 
they were fit and allowed to exercise.
O’Mara stresses that these are
preliminary results, but they offer hope
for the many people affected by the
severe side-effects of what was once
thought to be a wonder drug.
Break a protein,
make a memory
What happens in your brain
cells when you store a new
memory is very similar to
what happens when memories
are erased in Alzheimer’s
disease, researchers at UCD 
have found
If we understood how new memories
were stored in healthy brains, it would
help us understand how memories are
lost in Alzheimer’s disease. So Prof
Ciaran Regan and his research team 
at UCD’s Conway Institute study what
happens when they teach rats a new
trick. They are particularly interested in
a long protein called amyloid precursor
protein (APP), which is known to play
an important role in both learning and
Alzheimer’s disease. Indeed, the main
characteristic of Alzheimer’s disease 
is that an insoluble fragment of APP,
called beta-amyloid (Aβ) accumulates 
in the brain, forming deposits that seem 
to kill the surrounding nerve cells. But
what happens to APP in healthy brains?
Analysing brain samples taken from rats
at two-hour intervals after they had
learned to avoid a shock, revealed that
one of the first steps in creating a new
memory is that the APP is brought from
the outer nerve cell surface inside the
cell, where it is chopped into fragments.
This movement helps loosen existing
nerve cell connections, allowing a new
pattern to emerge and so store the new
memory. When the researchers blocked
the protein that moves APP into the
nerve cells, the rats were not able to
remember their new trick. They found,
too, that most of the chopping, or
processing, of the APP happens in the
hippocampus, the part of the brain
most associated with learning and
memory. Perhaps most significantly,
they discovered that the enzyme that
chops the APP is the same enzyme that
produces the insoluble, toxic fragment
seen in Alzheimer’s disease. This
reveals an important link between APP,
learning and Alzheimer’s disease.
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Why cannabis 
is bad for 
young brains
In an important study 
with major implications,
pharmacological researchers
at TCD have discovered that
cannabis kills nerve cells in
young brains
Cannabis seems to protect adult brain
cells, but actually causes young brains
cells to self-destruct. That’s the finding
of a study at TCD’s physiology
department that looked at the drug’s
effects on brain cells and brains. This
may explain how the drug can cause
brain damage to an unborn foetus, and
why the age at which someone starts
using the drug is important.
As a drug, cannabis is potentially
useful: it can kill cancer cells, for
instance, by causing them to ‘self-
destruct’, a process scientists call
apoptosis; and it can protect adult brain
cells from damage and degeneration.
But on the downside, it can trigger
psychosis or schizophrenia in some
users, and cause brain damage in
infants exposed to the drug while in 
the womb. 
To understand how the drug works,
pharmacologist Dr Veronica Campbell
and PhD student Eric Downer study
brain cells derived from young rat
brains and grown in the laboratory 
at TCD’s physiology department. They
discovered that the active ingredient
(tetra-hydro cannabinoid, or THC),
caused the cells to self-destruct, and
just as with cancer cells, it did this 
by binding to a protein on the cell 
and triggering a chain of events that
culminates in apoptosis. Since this is
different to THC’s effects on adult cells,
Campbell and Downer wondered if the
age of the cells was important. So they
next studied THC’s effects on adult 
and immature rat brains, and
discovered that age is crucial: THC
does not kill cells in adult brains, but it
does trigger apoptosis in immature
brains. Campbell next wants to study
how the drug affects adolescent brains,
to see if this can explain the drug’s
damaging effects in some adolescent
users. Meanwhile, she believes we
need to warn women, especially
teenage girls, to avoid cannabis if they
might be pregnant.
Transports of
delight?
Serotonin in the brain 
can affect our mood and
behaviour, but how is it
transported from cell to cell?
Biochemists at TCD are
investigating
Sleep, appetite, mood and pain…
just some of the behaviours and
neurological processes influenced by
serotonin. That’s quite an impact for 
a small molecule, but serotonin is a
neurotransmitter – a signalling molecule
that nerve cells in the brain use when
sending a chemical message to
neighbouring neurons – and disruptions
to the body’s serotonin system are
thought to be central to many
neurological disorders. So scientists
worldwide are studying how serotonin
is regulated and transported, work that
has already led to the current
generation of antidepressants, the 
selective serotonin re-uptake inhibitors
(SSRIs) that include Prozac.
At TCD, biochemist Prof Clive Williams,
Dr Jana Haase and PhD student
Francesca Magnani have characterised
one crucial regulator of serotonin levels,
the serotonin transporter protein. This
sits on the surface of neurons near
junctions with other cells, and is itself
thought to be tightly regulated, possibly
by binding with other proteins that can
increase or decrease its activity,
resulting in more or less serotonin being
transported in and out of the neurons,
and thus regulating the amount of
neurotransmitter available for signalling
to neighbouring cells. Williams’s team
identified one such regulator, syntaxin
1A, and found that, in the laboratory 
at least, it prevents the serotonin
transporter from functioning. They also
found that syntaxin 1A does indeed
bind to the transporter protein, and that
both proteins occur together on the 
cell surface, in specialised regions
called rafts. They now plan further
experiments to see if these reactions
also happen in real life, work that will
help shed light on these important
mood-modifying molecules.
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Genes and
autism
Genetic studies at TCD 
have successfully identified
one gene that is associated
with autism
Severe autism affects about one person
in every 1,000, but milder forms are
more common, affecting perhaps one 
in every 250.  While it is still not known
what causes the problem, it is now
clear that autism can run in families 
and there is good evidence to suggest
genes are involved, possibly as many
as 20 genes. Among those trying to
untangle this puzzle is psychiatrist 
Dr Louise Gallagher, who researches
autism genetics at TCD. Her group has
now conducted studies with 200 Irish
people and over 1,000 people from
other countries, and identified several
genes that are associated with autism
in the Irish population. One of these is
located on a particular region of
chromosome No 2, which researchers
elsewhere also believe may be linked to
autism. But what do these genes do?
Two interesting genes that the TCD
group has studied are: the serotonin
transporter, which codes for a protein
that transports the neurotransmitter
serotonin, and dopamine beta
hydroxylase, which codes for an
enzyme that converts another
neurotransmitter, dopamine, to
noradrenaline. The enzyme is
particularly interesting as it may
influence the severity of the disorder,
and Gallagher found that children with
autism have more enzyme in their blood
than normal. Most recently, with PhD
student Judith Conroy, the group has
identified another gene associated with
autism, and which is known to influence
the connectivity between cells. 
This finding has yet to be published,
but this gene may affect the ability 
of nerve cells in the brain to make
connections, and the next step would
be to investigate the gene’s function
further.  All of which research is helping
shed light on this complex and 
puzzling disorder.
Characteristics
of Autism
Autism is characterised by severe
problems in communication and
behaviour and an inability to relate
to people in a normal manner. 
The outstanding characteristics 
are extreme aloneness, difficulty 
in relating to other people, severely
impaired or no speech, insistence 
of the preservation of sameness,
intellectual impairment in some
areas - sometimes accompanied by
normal or superior skills in other
areas such as arithmetic, music, 
art or memory. 
Autism occurs more frequently in
males than females (approximate 
4:1 ratio). There are between 1200
and 2000 children and young adults
with autism in Ireland, increasing 
at a rate of some 100 new cases
every year. Recent studies in Ireland
found an incidence rate of 15 per
10,000 births. 
Source: Irish Society for Autism
THE DAUNTING
STATISTICS 
FOR DIABETES IN
IRELAND ARE:
200,000 PEOPLE IN
IRELAND HAVE
DIABETES. A
FURTHER 200,000
Diabetes:
Understanding a
common condition
“The daunting statistics 
for diabetes in Ireland are:
200,000 people in Ireland have
diabetes. A further 200,000
people in Ireland have diabetes
but are unaware they have it.” 
Source: Diabetes Federation of Ireland
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Coping better
with diabetes
Health psychologists at TCD
have identified psychological
factors that can help people
to manage their diabetes
Why is it that some people with
diabetes can manage their disease
better than others? Is it because their
disease is more stable and easier to
manage? Or because they have a more
positive attitude, which makes it easier
for them to cope? Health psychologist
Patricia White and Prof Tom O’Dowd, 
of TCD’s department of Public Health
and Primary Care, set out to investigate
this, first talking to patients and their
families in small focus groups, and then
with a larger survey of patients
attending diabetes clinics.
They looked at two types of people:
those with good control of their
disease, and those with poor control. 
A crucial factor seems to be the
person’s attitude and perception.
People with poor control are more likely
to be distressed or angry about their
diabetes, and to have trouble sticking
to a diet. Their way of coping with the
problem is, as it were, to avoid it, 
by using distracting therapies. In
contrast, those with good control of
their symptoms are more likely to tackle
any problems that arise. Armed with
this information Ms White is beginning
a new study, to see if people with poor
control of their disease can be helped
to devise better coping strategies.
Significantly, the current study also
found that many patients have a poor
understanding of diabetes and its 
long-term implications, suggesting 
that health professionals need to look
at how and when information is
presented to people.
A nutrient that
makes you 
make insulin
Biochemists at UCD have
discovered that glutamine
prompts your pancreas cells
to make the hormone insulin
When someone develops Type II
diabetes, the first thing that happens 
is that their body stops responding 
to insulin. Their muscle and fat cells, 
for instance, no longer respond to 
the hormone, and no longer take up
glucose from the blood. Result: blood
glucose levels rise. Then their pancreas,
which normally produces insulin, starts
to fail, so their insulin levels drop, and
their blood sugar problems get worse.
To understand why this happens, 
Dr Philip Newsholme and PhD student
Mary Corless are studying the detailed
biochemistry involved in insulin
production. 
Using state-of-the-art technologies
which are unique in Ireland, they study
pancreatic cells in the laboratory and
monitor how the beta cells, which
produce the insulin,  respond to
different nutrients. In this way they
identified a key nutrient, an amino acid
called glutamine, that helps the beta
cells to survive. Glutamine is produced
when proteins are digested, and plays
an important role in various tissues. 
In the brain and liver, for instance, 
it is involved in the synthesis of
neurotransmitters and urea respectively.
Its role in the pancreas was not known
until the UCD team discovered that 
it stimulates the cells there to begin
insulin production, news which they
have now published internationally.  
The next step, Dr Newsholme says, 
is to discover what is actually
happening – how glutamine switches
on the insulin gene, for instance –
information which might one day lead
to better treatments for diabetes. 
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liver stem cells (yellow) positive for both CD45
(green) and CD34 (red)
When blood
vessels are
damaged
Why are people with diabetes
prone to cardiovascular
trouble? Pharmacologists 
at UCD found that an enzyme
is part of the problem
Heart attack, stroke, poor circulation,
even gangrene…just some of the
serious cardiovascular complications
that can arise for people who have 
Type II, or late-onset diabetes. Now,
you may be wondering, how trouble
with high blood sugar levels can cause
such problems. The root cause, it
seems, is that high blood sugar levels
can increase the concentrations of
certain energetic oxygen molecules
circulating in the blood, and these 
can damage the endothelial cells that
line the blood vessels. 
To investigate what exactly is
happening, Dr Alan Keenan and PhD
student Erika Harno examined samples
of blood vessels taken from a strain of
laboratory rat that is prone to Type II
diabetes. They found that, if the rats
had diabetes, a crucial enzyme did not
work properly: instead of producing
nitric oxide in response to insulin, 
this nitric oxide synthase enzyme
produced a damaging superoxide
molecule. Result: damaged blood
vessels. Studies elsewhere have shown
that folic acid (one of the B vitamins),
and certain drugs called ACE inhibitors
can help counter this damage. Keenan
thinks they do this by helping the
enzyme to work more efficiently, 
and next he hopes to study how these
compounds interact with insulin 
and with the enzyme.
The current study threw up another
important finding: at higher insulin
doses the mis-functioning enzyme
produces even more superoxide. 
Yet high doses of insulin are sometimes
used to treat diabetic patients who
have had a heart attack. Keenan warns
that their findings mean this approach
should be taken with caution.
Image caption: small blood vessel in alveoli 
Protecting cells
from the ravages
of diabetes
Could a simple dietary
supplement protect cells from
some of the damaging effects
of diabetes? Two TCD
biochemists think so
Taurine is a small yet fascinating
molecule. A type of amino acid, it 
was first isolated from beef – the name
comes from taurus, Latin for bull – 
but most of our tissues actually have
lots of it, which suggests it does
something important. Our bodies
synthesise taurine, but we also get 
it from our diet, and large amounts 
are added to some dietary supplements
and soft drinks. Despite the bullish
name, taurine’s main functions seem 
to be protecting our cells from damage.
The molecule has fascinated Prof Keith
Tipton for decades, and with PhD
student Joseph Healy he recently
investigated taurine’s role in two 
very different situations: nerve death,
and diabetes.
Giving a toxin called MPTP to
laboratory rats will cut off the energy
supply to their nerve cells, resulting 
in a condition similar to Parkinson’s
disease. But Tipton and Healy found
that, if the rats are first given a taurine
supplement, this protects their nerve
cells from damage by the toxin.
However, give the rats too much 
taurine and, mysteriously, the 
effect disappears.
To investigate taurine’s role in diabetes,
Tipton and Healy, collaborating with
colleagues in Italy, gave laboratory 
rats streptozotocin, a toxin that kills the
pancreatic cells which produce insulin.
As a result, the rats developed insulin-
dependent diabetes, when, typically,
blood sugar levels rise and fat cells 
can no longer take up glucose. But as
before, if the rats were first given
taurine, their fat cells were somehow
protected and continued to take up
glucose as normal. Significantly, these
rats did not experience the tissue
starvation normally seen in diabetes,
although their blood sugar levels were
still high. This suggests that some
diabetes patients might benefit from
taking taurine along with their glucose-
lowering drugs, though clinical trials
would be needed to confirm this. 
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When your
kidney becomes
fibrous and fails
Cell biologists at UCD are
chasing new drugs that could
prevent kidney disease in
diabetic patients
Of all the complications of diabetes,
one of the worst is kidney failure, which
leaves many patients needing dialysis
or, worse, a transplant. Connective
tissue and collagen start proliferating
and invade the kidney, and the kidney
cells’ internal skeleton or scaffolding
becomes disrupted. Result: diabetic
nephropathy. In 1994, scientists
described the proteins or ‘growth
factors’ that drive these changes and
that are somehow activated by high
blood sugar levels. Now, a handful of
specialist research teams worldwide
study the detailed biochemistry of these
growth factors, including scientists at
UCD’s Conway Institute. There, cell
biologist Dr John Crean and Prof
Catherine Godson have pieced together
the steps involved for the connective
transforming growth factor, alias CTGF. 
Like other growth factors, CTGF 
has diverse functions, but in fibrotic
disorders it seems to specifically drive
the accumulation of connective tissue.
Hence it is a possible target for
treatments in diseases such as diabetic
nephropathy. US company Fibrogen,
which owns the rights to CTGF, already
has promising results from early clinical
trials with an antibody that knocks out
CTGF, and the firm supplied purified
CTGF to UCD. This allowed Dr Crean 
to discover that CTGF first binds to 
a particular cell surface molecule, 
and that this releases two biochemical
signals that tell the cells to produce
more fibronectin and collagen. Crean
found that increased levels of CTGF 
are probably also responsible for
disrupting the kidney cells’ skeleton.
These fundamental biochemical
discoveries are helping the US
company to refine its clinical trials, 
and the UCD researchers are now
screening potential drug compounds
that block CTGF, as an alternative to
antibodies for treating fibrotic diseases.
A gremlin in the
kidney works
The gremlin gene damages
the kidneys of people with
diabetes but, as UCD
researchers have found,
embryos need the same 
gene for their kidneys to
develop properly
People with diabetes often develop
kidney failure. Their kidneys can
become scarred, the kidney cells may
grow wildly, and the filtering channels
can become blocked and eventually
fail.  When that happens, the person
will need dialysis or, worse, a
transplant. In 2000, researchers at
UCD’s Conway Institute discovered 
that a gene called gremlin was involved
in this diabetic kidney disease. 
The more active a person’s gremlin
gene, the worse their kidney disease
was likely to be. But what is the normal,
healthy function of this gene? 
To investigate, Dr Vincent Dolan, 
a kidney consultant, teamed up with 
Dr Carmel Hensey, who studies how
tadpoles develop.
Together, they discovered that gremlin
is essential for healthy kidney
development in the embryo.  So
essential, that it has changed little
in millions of years and frog gremlin 
is very similar to human gremlin, even
though frog kidneys are much simpler
than ours. Dolan and Hensey found 
that if there is little or no gremlin activity
(if they knocked out the gremlin gene,
for instance), tadpoles develop only 
a rudimentary kidney at most; and with
too much gremlin activity, they develop
extra kidneys. Normally, the gene is
switched off in adults, but in diabetic
kidneys it somehow switches on again,
triggering inappropriate growth that
damages the tissue. The scientists
hope that, if they can understand 
how gremlin does this, it could lead 
to a treatment that would prevent 
this damage.
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What is diabetes?
Diabetes Mellitus, or just diabetes 
as it is more commonly known,
occurs when the sugar (glucose)
level in the blood is too high. 
This happens when the body is 
not burning up carbohydrates
properly due to a defect in the
pancreas, the gland that produces
insulin. Insulin is the hormone which
keeps blood sugar levels within the
normal healthy range. Diabetes may
be present either when no insulin 
is made or when insulin is made 
but not working properly.
There are two types of diabetes -
type 1, or insulin dependent
diabetes, which usually occurs
before the age of 35. A person with
type 1 diabetes makes no insulin 
and therefore needs to inject insulin
to regulate blood sugar levels and
remain healthy. Type 2, or non-insulin
dependent diabetes usually occurs 
in adults after the age of 40 and 
is extremely common in old age. 
In this case, the person with diabetes
makes some insulin, but this does
not function properly. Usually
associated with being overweight,
this condition responds well to
weight loss through dietary
regulation. Sometimes weight loss 
is not enough and tablets are
required to help the person's own
insulin to work. This type of diabetes
is also known as adult-onset or
maturity-onset diabetes.
With an average of seven years
between onset and diagnosis, 
the earlier the condition is detected
the easier it will be to manage. 
Early detection gives the ability 
to protect against heart attack.
Diabetes is considered by the World
Health Organisation (WHO) as a
growing epidemic with present
numbers of people affected by
diabetes set to double over the next
10 years to 240 million worldwide.
The incidence of the disease in 
Irish adults is also expected to rise
dramatically in the immediate future
as a direct result of the growth in
obesity. It is estimated that up to
75% of the risk of type 2 diabetes 
is caused by obesity.
The daunting statistics for Diabetes
in Ireland are: 200,000 people in
Ireland have diabetes. 200,000
people in Ireland have diabetes 
but are unaware they have it. 
A further 250,000 people have
impaired glucose tolerance or 
“pre-diabetes” of which 50% 
will develop diabetes in the next 
5 years if lifestyle changes are 
not made.
One of the most disturbing trends 
in the area of diabetes at present is
the growing number of children now
being diagnosed with type 2, where
traditionally this was a disease of 
the over 50s. The reason for this is
lifestyle, and in particular obesity.
Source: Diabetes Federation of Ireland

THANKS TO NEW
GENETIC
TECHNIQUES,
SCIENTISTS ARE
DISCOVERING HOW
CERTAIN CANCER
DRUGS WORK,
AND THE
Cancer: 
Tackling the big C
“Thanks to new genetic
techniques, scientists are
discovering how certain cancer
drugs work, and the information is
helping to identify which patients
will respond well to the drugs.”
Source: ‘Genes, drugs and cancers’, Prof Mark Lawler and colleagues (St James’s Hospital) 
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New screening
tests for colon
cancer
Two clinical research teams
are developing new tests 
and approaches to screen 
for colon cancer in Ireland
If colorectal cancer can be detected
early, then the prognosis is excellent,
with 97% of patients surviving to the
crucial five-year point. But that’s a big
‘If’, and it all depends on having an
accurate and effective screening test.
The current ‘gold standard’ is
colonoscopy, but this is invasive, time-
consuming and costly. The alternative 
is a test for blood in the stool (the
faecal occult blood test, or FOBT),
which is relatively cheap and quick, 
but only about one-third as effective 
as a colonoscopy, and it misses up 
to 50% of cancers. Clearly, we need 
a better screening test, and in 2003 
a German company, ScheBo, released 
a commercial test that looks promising.
Now, gastroenterologist Prof Colm
O’Morain, of the Adelaide & Meath
Hospital, Tallaght, with Dr Ramona
McLoughlin and PhD student Ellen
Shiel, have given the German kit its 
first independent clinical trial.
The kit tests for the presence in stool
samples of an enzyme, called M2-PK.
This enzyme is closely associated with
several cancers, and so its presence 
in stool samples would indicate 
the existence of colorectal cancer. 
The Tallaght team tested stool samples
from 162 patients, of whom 97 had 
a normal colonoscopy, 30 had pre-
cancerous growths (adenomas), and 
35 had colorectal cancer. They found
that the new kit performed well,
detecting 97% of the cancers, and 
76% of the adenomas that had been
detected by colonoscopy. While this
trial was relatively small, it suggests
that the stool M2-PK test has great
promise in screening for colorectal
cancer. As an added plus, the new kit 
is analysed using a technique known 
as ELISA that is ideal for automated
mass screening. 
Meanwhile, at St Vincent’s University
Hospital in Dublin, Dr Kieran Sheahan
and colleagues have validated a new
screening test for familial forms of the
disease. Some 5% of all colon cancers
are known to be inherited, and if a 
hereditary form is diagnosed, then 
other family members who may be 
at risk need to be identified. But with
increasingly smaller families, the
traditional family history approach 
is difficult, so a new generation of 
test focuses on what happens at 
the DNA level. 
Most familial colon cancers develop
when someone lacks a working version
of one of the enzymes responsible for
repairing errors in DNA. Errors
accumulate, notably multiple copies 
of short DNA sequences, called
microsatellites, and the new test works
by screening for certain microsatellite
patterns. Sheahan found that the test
successfully picks up 60% of the
known familial cases (in other words,
detects 3% of all colon cancers). This
complements an existing antibody test
that can tell which DNA repair enzymes
are present or absent. Happily, people
with some forms of familial colon
cancer have a good prognosis –
possibly because their distinctive
tumours provoke a strong immune
reaction which helps fight off the cancer
– but intriguingly, their tumours do 
not respond well to the usual
chemotherapeutic drugs, so an added
benefit of these tests is identifying
cases where other approaches should
be used. This makes the antibody and
new microsatellite test especially useful. 
Sheahan believes that all colon cancer
patients should be screened with these
tests, so that other ‘at risk’ relatives 
can be identified quickly, and having
validated the microsatellite test for Irish
families, his team is now a reference
centre for other Irish diagnosis units.
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Cancer,
commuting and
quality of life
Regional treatment centres
would make life much easier
for families who currently
have to bring a child to
Dublin for cancer care, 
a UCC study finds
It’s bad enough if your child is
diagnosed with cancer or leukaemia,
but if they have to travel long distances
to Dublin for treatment, that brings
added difficulties. In Ireland, primary
cancer care is effectively centralised 
in Dublin, and 16 of the 17 regional
‘shared care centres’ provide only
emergency care. Dr Peter Kearney, 
a consultant paediatrician at Cork
University Hospital, wondered how 
this affects the families, and how other
countries provide care in regions with 
a similar low-density population. 
He and child psychologist Dr Anne
Gaffney and researcher Brenda Morris
interviewed families and specialist
nurses in Ireland, and cancer experts
here and in Scotland, Wales and Bristol
in southwest England.
If families cannot make the round trip 
to Dublin in one day, the travelling 
can mean major disruption, prolonged
separation, sibling neglect and money
worries, especially if it entails lengthy
stays away from home. In the UK, 
the team found, these problems are
largely averted by providing primary
cancer care at regional level. In other
words: there it’s the consultants who 
do the travelling, not the families. 
This means the regional centres need
additional resources and infrastructure,
and expert staff, but already, Irish
neonatal care is being reorganised
along similar regional lines. Kearney
believes that something similar is
needed for cancer care, and that this
would be a tremendous boon for
families coping with childhood cancer.
Genes, drugs
and cancers
Research at Dublin’s St
James’s Hospital is helping 
to predict which patients will
respond well to cancer drugs
Thanks to new genetic techniques,
scientists are discovering how certain
cancer drugs work, and the information
is helping to identify which patients 
will respond well to the drugs. At the
Institute of Molecular Medicine in 
St James’s Hospital, Prof Mark Lawler,
Prof Shaun McCann, Dr Eibhlin
Conneally, PhD student Lorraine Tracey
and postdoc Dr Kathy Gately, are
investigating interferon alpha (INF-α),
which is used to treat cutaneous 
T-cell lymphoma and chronic myeloid
leukaemia (CML), and imatinib mesylate
(brand-name Glivec), also used to 
treat CML.
Glivec is one of the new molecular
medicines: designed specifically to
interact with a molecule in the cancer
cells, it promises to revolutionise CML
treatment, which until now usually
needed a bone marrow transplant. 
The team has developed a molecular
test to monitor the progress of patients
taking Glivec, and they discovered that,
when a patient becomes resistant to
the drug, this is often due to mutations
in the gene for a kinase enzyme. This
information may help improve the next
generation of drugs, or identify drugs 
to be taken in combination with Glivec. 
For the cutaneous T-cell lymphoma,
which manifests as skin lesions, the
researchers – in collaboration with the
National Cancer Centre in Madrid –
identified six genes that are altered 
in the cancers. This genetic signature
could be the basis of a test for this
disease, which can be difficult to
diagnose. The team also identified 
a genetic signature, involving some 
40 genes, for patients who respond 
well to INF-α treatment. If these can 
be narrowed down to a handful of key
genes, it could form the basis of 
a prognostic test to predict which
patients will respond to treatment.
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Keeping cancer
at bay after
surgery
Cancer researchers at 
Cork University Hospital 
are studying why some
cancers return aggressively
after surgery
It is a natural and understandable
reaction. Our immune system perceives
surgery as a wound, and responds 
with lots of immune cells and molecules
designed to promote healing and
regrowth. The question that researchers
at Cork are asking is, do these healing
and growth promoting substances
affect any cancer cells that might 
be present. It is an important question,
as cancer surgeons can’t always be
sure they have removed every last
cancer cell. Increasingly, evidence,
much of it from research at UCC,*
suggests that the immune response 
to surgery can indeed make cancer
cells grow aggressively. Now, cancer
surgeon Dr Calvin Coffey and
colleagues at UCC’s University Hospital
have investigated how this might 
be happening.
Studying tumours taken from laboratory
rats and from biopsies donated by
cancer patients, they discovered that
several genes are turned on in tumour
cells after surgery. The genes are
involved in a process called the PIC-
kinase pathway, and the net effect is to
make the cells grow and in such a way
that they become resistant to several
chemotherapy drugs. However, if the
researchers treated the cancer cells
with a chemical that blocks the PIC-
kinase pathway, they found they could
reverse the change and almost ‘tame’
the tumours. But the tumours still grew,
albeit more slowly, suggesting they can
use an alternative pathway, one Coffey
hopes to identify soon. Clinical trials
with patients are still some way in the
future, but these latest results confirm
that surgery can, perversely, stimulate
the tumour it was intended to kill.
*Last year, we reported on related
research from another Cork team, who
discovered that tumours in lab rats are
less likely to return after keyhole
surgery, than after more intrusive open
surgery, probably because keyhole
surgery does not provoke such a strong
immune response.
How cells
control their 
self-destructive
tendencies
Cell biologists at TCD have
worked out how a particular
protein regulates cell suicide
The cells in your body have a self-
destruct mechanism. It’s how they
remove themselves from the scene
when their job is done, or they have
become old, damaged or infected.
Scientists call the process apoptosis,
and it’s tightly regulated by a complex
interplay of numerous controlling
mechanisms so that it happens only
when it should. Sometimes, however,
the controls become faulty and cells
commit suicide when they should not –
if eye cells did that, for instance, you
would go blind – or they don’t self
destruct when they should, in which
case they proliferate and form tumours.
One protein that helps keep apoptosis
under control is called Smac, and 
Dr Emma Creagh, working with Prof
Seamus Martin at TCD’s genetics
department, has now pieced together
the Smac picture. Creagh has
discovered that Smac is normally kept
under wraps in a special compartment
in the cell and only released when 
the cell is fully committed to self
destructing. Smac’s release is normally
held in check by another protein, called
Bcl-2; many cancer cells have higher
than normal amounts of Bcl-2, so this
explains why they can no longer release
their Smac and trigger self-destruction.
Significantly, Creagh discovered that
Smac’s role is to ensure that the
caspase enzymes which essentially
dismantle the cell can get to work, 
and that Smac does this by inhibiting
the proteins that normally inhibit the
caspases. There is now growing
interest in drugs that can mimic Smac
and force cancer cells to die. Clinical
trials of several are underway, and 
the TCD research has helped the
pharmacologists to understand how 
the new drugs work.
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Software – 
for a better
fitting drug
Pharmaceutical chemists at
TCD have designed computer
tools for drug design that
have already helped identify
possible new drugs to fight
breast cancer
Time was when drug designers relied
on serendipity and ‘hit and miss’
screening to identify new drugs. 
These days they’re more likely to use
computers to design the perfect drug,
exploiting powerful software, DNA
sequence information, and 3D pictures
of what a particular target protein looks
like, combined with detailed chemical
data about how the existing drugs
work, to produce improved designs
which can then be tested in the lab. 
At TCD, pharmaceutical chemist 
Dr Mary Meegan wants to design new
drugs for breast cancer, perhaps more
effective or with fewer side-effects 
or cheaper to manufacture than the
current drug, tamoxifen. Tamoxifen 
acts by binding to oestrogen receptor
proteins in breast cancer cells;
oestrogen normally binds there, 
and switches the cells into proliferation
mode, but when tamoxifen binds 
it changes the receptor’s shape 
and prevents oestrogen from binding
and the cells from proliferating.
Meegan, colleague David Lloyd and
PhD student Andrew Knox use software
written by their collaborator, Vladimir
Sobolev of the Weizmann Institute, 
to assess computer models of
hundreds of chemicals and how well
they interact with the oestrogen
receptor. They confirm the fit by testing
the compounds on breast cancer cell
lines in the lab. Significantly, they have
devised a new and powerful scoring
system to rate how each compound 
fits with the oestrogen receptor,
something they may be able to
commercialise. Already, they have
successfully identified several hopeful
candidates, new would-be tamoxifens,
and these will shortly be tested on
breast cancer cells in a follow-up study.
Image caption: Three crystal structures of the
oestrogen receptor are shown superimposed 
on the computer screen. The platforms emerging 
from the computer represent the levels of screening
from (a) cavity analysis of receptor binding site 
to (b) ligand complementary volume to (c) selection 
of ligand to (d) docked structure. 
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Chernobyl,
radiation and
thyroid cancer
Some 18% of thyroid cancers
among Irish patients could 
be due to radiation similar 
to that released by the
Chernobyl disaster, a TCD
study suggests 
The most common form of thyroid
cancer is papillary thyroid cancer (PTC),
so-called because the tumour is
covered with nodules or papillae.
Fortunately, PTC seldom kills. But that
changed with the Chernobyl disaster,
when a new and more lethal form of
PTC became common in children there.
In the 1990s, geneticists discovered
that this Chernobyl form was
associated with a particular
rearrangement of chromosome 10:
essentially, a chunk of DNA flipped
over, bringing together two genes that
were normally located far apart.  
This change, called ret/PTC3, left one
particular gene permanently switched
on, driving a process (known as the
MAP-kinase path), which causes
thyroid cells to grow wildly. A different
rearrangement, called ret/PTC1, is seen
in the less aggressive, classical PTC. 
Dr Stephen Finn has now found the
Chernobyl rearrangement in 18% of
Irish papillary thyroid cancers, although
the Irish cancers are not identical to
those seen in Chernobyl – for example,
their appearance under the microscope
is slightly different. 
Significantly, by irradiating cells in the
laboratory, Dr Finn has discovered that
the Chernobyl rearrangement is caused
by gamma radiation, such as given off
by caesium-137 (the main radioactive
isotope released by the Chernobyl
explosion); conversely, beta radiation
(as given off by radioactive iodine), 
and X-rays can cause only the classical
rearrangement. However, this is not 
to say that 18% of thyroid cancers here
are due to Chernobyl, as more data
would be needed to rule out other
sources. 
Dr Finn, who is part of a thyroid cancer
research team led by Dr Orla Sheils at
TCD's department of histopathology,
also discovered that the gamma
radiation acts by removing part of 
the protective cap at the end of
chromosome 10, which may make the
chromosome more sticky and more
liable to rearrangement. Intriguingly,
chromosome 10 is particularly
vulnerable, possibly because its
position in the nucleus of the cell is
more exposed.
In characterising Irish thyroid cancers,
Dr Finn identified a new risk gene,
platelet-derived growth-factor receptor-
beta (PDGFRB), the first time this gene
has been associated with thyroid
cancer. The gene acts in the same
MAP-kinase path as ret/PTC and may
account for a further 20% of Irish
thyroid cancers.  Finally, the TCD study
identified several other genetic changes
associated with thyroid cancer and they
are now working with industrial partners
to design better diagnostic tests.
Current tests are imprecise, and surgery
is often needed to confirm a diagnosis,
so a better test would save many
people from unnecessary surgery.
…A LITTLE
INFLAMMATION IS
A GOOD THING..…
A LITTLE
INFLAMMATION IS
A GOOD THING 
…A LITTLE
INFLAMMATION IS
Immune affairs: 
The battle rages
“…a little inflammation is 
a good thing.”
Source: ‘Parasites, hygiene and allergy’, Dr Deirdre Campion (Veterinary science, UCD) 
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Viruses and 
you – it’s an
arms race!
A better understanding of 
our immune system is coming
from research under way 
at TCD
It’s an arms race. Your body’s immune
system constantly works to detect 
and destroy viruses, and the viruses
fight back by developing ways to slip
past the ‘radar’, evade capture and
even subvert the immune system to
their own end. And Vaccinia, the virus
that is the basis of the smallpox
vaccine, is particularly good at this,
because it can disable our body’s alarm
system. The alarm depends on
molecules known as the toll-like
receptors (TLRs), which normally alert
your body to the presence of an invader
and set the immune system to attack.
But Vaccinia produces two proteins 
that disable the alarm, by inhibiting the
biochemical pathways that are triggered
by the TLRs. This allows the virus to
survive inside our cells and explains
why, occasionally, a Vaccinia vaccine
can make some people ill. 
TCD biochemists Dr Andrew Bowie 
and PhD student Geraldine Maloney
have now studied what one of the viral
proteins, known as A52R, does inside
our cells, and found that it binds to 
two different alarm proteins, IRAK2 
and TRAF6. By binding to IRAK2, 
they found, it turns off the processes
that would normally switch on a suite 
of genes aimed at eliminating the virus.
By binding to TRAF6, it turns on other
processes that produce more
interleukin-10, a protein that allows
viruses to survive for longer in the body.
So, not only does A52R evade the
immune response by blocking TLR
effects, it also subverts the TLR system
for its own purposes. This TCD work
has improved our understanding of 
how the immune system deals with
viruses, and may one day help us
design better vaccines.
Getting back to
normal after
inflammation
Shape-shifting cells are
important in resolving
inflammation, UCD cell
biologists have discovered
Shape-shifting doesn’t just happen in
sci-fi movies – it can also be important
in determining how cells function in the
body.  And cell biologists at UCD’s
Conway Institute have discovered it
plays an important role in restoring
normal function after inflammation.
Inflammation is an important aspect 
of our body’s defences, but chronic
inflammation is the basis of several
serious illnesses so it is important to
restore normal function quickly. Prof
Catherine Godson and PhD student
Keira Reville are investigating one
important mechanism involved: the
specialised macrophage cells that 
clear away dead and dying cells which
accumulate at inflamed sites, and 
how this task is controlled. The dying
cells normally remove themselves from
the scene by following a ‘cell suicide’
programme called apoptosis. These
apoptotic cells have to be removed,
however, before they burst and release
their potentially toxic contents. Enter
the macrophage, a cell that can engulf
them, a process helped along by lipid
or fat-like molecules called lipoxins,
which are naturally produced in 
the body. 
Prof Godson and her team have now
discovered that lipoxins function by
triggering changes in proteins inside
macrophages causing them to change
shape. This change ‘primes’
macrophages and enables  them to
engulf more dying cells – increasing
their appetite, as it were. A specific
protein in the macrophage, called
myosin, seems to be crucial: when the
researchers blocked myosin, the
macrophages could no longer respond
to the lipoxins: they did not change
shape, and did not consume more
dying cells. This finding helps us
understand how inflammation is
resolved, and may suggest new ways
to treat chronic inflammatory conditions
associated with inadequate removal 
of dying cells.
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Finding a 
system that
controls lung
inflammation
Medical researchers at the
Royal College of Surgeons
are investigating how our
immune system switches
inflammation on and off
If you have a lung infection, your
immune system will react and try 
to protect your lungs by mounting 
an inflammatory response. But
inflammation, while necessary 
to fight infection, can be harmful if 
it continues and so, once the infection
has cleared, your body has to be able
to switch the inflammation process off.
At the Royal College of Surgeons 
in Ireland, Dr Clifford Taggart is
investigating just how the immune
system does this.
One of the main proteins orchestrating
the inflammatory response is called
nuclear factor κB (NFκB), which works
by binding to DNA in the cells, and
switching on genes that code for 
pro-inflammatory proteins. In healthy
cells, NFκB is normally prevented from
binding to the DNA by what are called
the inhibitory κB (IκB) proteins. When
inflammation is needed, these IκB are
taken out of the way, by being
chemically marked for destruction, 
and then degraded by various enzymes.
The cells normally switch off the
inflammation by producing anti-
inflammatory proteins, including one
called secretory leucoprotease inhibitor
(SLPI), and Dr Taggart’s research has
shown that this interacts directly with
DNA, thus preventing NFκB from
binding and from switching on the
inflammation genes. Taggart’s next step
is to study cells in biopsies taken from
patients who have chronic lung
inflammation, to see if the mechanism
he observed in cells in the laboratory 
is what actually happens in real life, 
and to find out what goes wrong when
chronic inflammation develops.
Parasites,
hygiene and
allergy
Physiologists at UCD’s
Veterinary College find that 
a little inflammation is good
for your gut
They call it the hygiene hypothesis. 
The notion that, if our immune system
is to work properly, then it must be
challenged early in life. And if this
doesn’t happen, the immune system
may respond inappropriately later in life,
leaving us prone to allergies and
problems such as inflammatory bowel
disease. As the intestine is exposed to
large numbers of foreign bodies and
pathogens it ought to be an important
site for immune system training. 
To investigate events there, gastro-
physiologists Dr Deirdre Campion and
Prof Alan Baird, and PhD student 
Ms Leah O’Brien, study the effects of 
infection with a parasite that causes
mild inflammation of the gut wall.
The team discovered that a little
inflammation is a good thing. It makes
the body produce more immune cells
and nerve cells. During infection, these
induce the gut to secrete more water,
resulting in diarrhoea, which helps flush
out the parasites. There is a long-term
benefit too: even after the parasite
infection has cleared, the gut wall
remains primed, and ready to respond
to any subsequent exposure to
parasites, bacteria or viruses. In effect,
the first mild infection makes your body
more resistant to later infections.
However, a severe parasite infection
seems to make the immune system
hypersensitive, resulting in chronic
inflammation and diarrhoea that can
persist for long after the original
infection has cleared. The results
suggest that training is important. 
The team’s next project is to look at
ways of exploiting this to prevent
Salmonella infections in hens, where 
it poses a health hazard if people eat
contaminated chickens or eggs.
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How an infection
can trigger an
asthma attack
At NUI Maynooth, cell
scientists have pieced
together a biochemical 
chain reaction that starts 
with an infection and ends 
with asthma
Thanks to the sequencing of the human
genome, scientists have identified
several genes associated with asthma.
But what do these genes actually do?
Scientists at NUI Maynooth’s Institute
of Immunology, led by Dr Bernard
Mahon, are focusing on one such gene,
which codes for a protein called CCL28
that is involved in signalling between
cells. They have now pieced together
much of the CCL28 story and can even
explain how a chest infection might
trigger an asthma attack. 
First, they cloned the gene, then made
CCL28 protein, and devised two ways
to measure how much CCL28 is
present in cells and secretions. 
Thus equipped, they discovered that
CCL28 is normally present at low levels
in the cells lining the airways and that,
in mice, CCL28 levels rise dramatically
during an asthma attack. Significantly
they also discovered that CCL28's role
is to physically mobilise certain immune
cells, the TH2 cells, which orchestrate
the inflammation associated with
asthma. Perhaps most interestingly,
they discovered that the presence of
another signalling molecule, IL-1β, 
will cause CCL28 levels to rise, and
IL-1β itself is already known to rise
when there is a bacterial infection. 
So Dr Mahon suggests that, first, 
an infection triggers higher IL-1β, 
which raises CCL28 levels, which
mobilises TH2 cells, which result in
inflammation. To test his hypothesis, he
next wants to see if CCL28 levels vary
in asthma patients with the severity of
the disease, and if drug treatments
work by lowering CCL28 levels. All part
of trying to understand a major disease
that is on the increase.
The white blood
cell that can
restrict your
breathing
Research at the Royal
College of Surgeons is
shedding light on the
mechanisms that trigger
asthma attacks
They are having asthma attacks in the
labs at the Royal College of Surgeons
in Dublin. Happily, these are small-scale
attacks, that take place in a dish when
nerve cells come in contact with a type
of white blood cell called an eosinophil.
Eosinophils are produced by the
immune system when it perceives a
threat; they are also involved in allergic
responses, and are found in tissues at
the site of allergies. Usually only a few
eosinophils are found – typically about
10 for every million other cells. So the
big question is: What are they doing?
At the RCSI, respiratory consultant 
Dr Richard Costello and research fellow
Dr Marie Therese Walsh discovered 
that eosinophils actually irritate nerve
cells. In particular, that they stimulate
the nerves to produce more of the
chemical signal which tells muscle cells
to contract. Net result: muscle cells will
contract more than they should, just as
in an asthma attack, when a person’s
airways contract. The RCSI team has
now discovered the detailed molecular
steps that happen when eosinophils
and nerve cells interact in the
laboratory, and in a new HRB-funded
project, will now see if these same
things happen in real life in people 
with asthma. By improving our
understanding of asthma, this work
might one day lead to better ways 
of treating the problem.
Liver stem cells
– and their many
career options
Cell biologists at St Vincent’s
University Hospital in Dublin
have uncovered an important
role played by stem cells in
the liver
Stem cells aren’t just for embryos –
these powerful cells, which can mature
into specialised cell types, are also
found in many adult organs. The best-
known adult ones are in the bone
marrow, where they give rise to new
blood and immune cells. There are
stem cells in the liver, too, and
researchers in Birmingham have
recently confirmed that these can give
rise to new liver cells, thus explaining
how the liver can regenerate following
damage and disease. But the liver is
also home to certain immune cells,
notably theso-called ‘natural killer cells’
that have potent anti-cancer and anti-
virus powers. An important question in
understanding liver function and the
immune system, is where do these 
cells come from?
At St Vincent’s University Hospital, 
Dr Lucy Golden-Mason studies
samples donated by patients having
liver biopsies, and she has just shown
that the immune cells in the liver are
generated locally, and from liver stem
cells. The Dublin and Birmingham
researchers are now collaborating to
see if there are two types of liver stem
cells – one for immune cells, and one
for liver cells – or if, as they currently
suspect, there is just one, which is
directed into one or other of the ‘career
options’ by factors in the liver.
Ultimately, by understanding what
prompts stem cells to mature and
specialise, we may one day be able 
to push the stem cells down targeted
career paths – into liver cells, to help
repair damaged tissue, or into immune
cells to fight cancer and infection.
Image caption: Liver stem cells (yellow) positive 
for both CD45 (green) and CD34 (red)
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The waste
product that can
do some good?
Increased CO2 levels seem 
to reduce inflammation,
which could benefit some
patients. But UCD scientists
wonder is there a downside
to this simple technique?
People who are gravely ill run the risk 
of lung damage. This happens if their
immune system responds to their
condition by flooding their lungs with
white blood cells, causing dangerous
inflammation. The search is on for ways
to prevent this, and tantalising results
from previous research have shown 
that if white blood cells in the
laboratory were treated with CO2, 
the cells lost their appetite for the fight.
Could it be that simply increasing the
CO2 levels in a patient’s body would
prevent lung damage in patients on 
life-support machines?
At UCD’s department of physiology, 
Dr Donall O’Croinin and colleagues 
are exploring the CO2 effect further. 
They are looking at what happens 
in animals, and asking, Is there a
downside? After all, if increased CO2
levels dampen down the immune cells,
shouldn’t this make the system less
able to fight infection? Sure enough,
O’Croinin found that rats are more likely
to develop damaging lung infections 
if they are given CO2. It is, O’Croinin
says, the two sides of the same CO2
coin: the very change that makes the
system less likely to cause
inflammation, also makes it less likely
to fight off infection. So, simple CO2
treatment will not be the perfect
therapy, but it may yet prove useful 
in certain conditions.
OVER THE PAST
DECADE,
SCIENTISTS AT
UCC CORK HAVE
ISOLATED AND
PATENTED TWO
NEW STRAINS OF
PROBIOTIC
Infections, microbes 
and gut feelings
“Over the past decade, scientists at
UCC have isolated and patented two
new strains of probiotic bacteria….. the
bacteria might be useful in alleviating
the chronic symptoms of inflammatory
bowel disease.”
Source: ‘Probiotics and gut reactions’, Prof Fergus Shanahan and colleagues (Microbiology, UCC)
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Probiotics and
gut reactions
Two new probiotic strains,
discovered and patented 
at UCC, have potent anti-
inflammatory and immune-
boosting effects that may
help alleviate inflammatory
bowel disease
Over the past decade, scientists at
UCC have isolated and patented two
new strains of probiotic bacteria,
selected from a long-list of several
thousand possibles. Most other
probiotics are, surprising though it may
seem, isolated from faecal sources, 
but the Cork two are unique in that they
were isolated from healthy gut samples
– the rationale being that faecal
bacteria could be mere passive
passengers through the gut, but that
anything that can live happily in our
intestine is likely to be on friendly terms
with our immune system, and therefore
likely to have interesting probiotic
effects. Now, in two related projects,
scientists in Cork have pieced together
how their bacteria work. The results are
promising, and suggest the bacteria
might be useful in alleviating the
chronic symptoms of inflammatory
bowel disease.
First, immunologists Prof Fergus
Shanahan and Dr Liam O'Mahony, 
with PhD student Padraig O'Regan,
working with lab mice, have proven 
that the two Cork probiotic strains
reduce the immune system’s production
of inflammatory molecules, while
stimulating production of anti-
inflammatory molecules, and that they
can do this whether taken orally or
injected under the skin. This is doubly
interesting: it proves the bacteria
directly affect the immune system, and
that their beneficial effects do not come
simply because they out-compete ‘bad’
bacteria in the gut; also, it suggests
that chronically ill people could benefit
from injections of high doses of the
probiotic bacteria, or active
components extracted from them.
The same team also looked at the
bacteria’s effects on the epithelial cells
which line the gut wall. They found 
that when the cells come in contact
with disease-causing Salmonella
bacteria, they switch a battery of genes
associated with immune defences, 
but the probiotic bacteria had no effect
at all, clear evidence that the gut cells
can tolerate these bacteria. The next
step is to identify the molecules on the
bacteria responsible for the beneficial
immune reactions.
In a related project at Cork University
Hospital, surgeons Eamon Kavanagh,
and Prof Liam Kirwan, with Dr
O'Mahony, and PhD student David
Shilling, studied how the dendritic cells
of the immune system react to bacteria
in the gut. Dendritic cells take suspect
bacteria and present them to the
immune system for assessment and,
thanks to samples donated by patients
undergoing surgery at the hospital, the
team can study dendritic cells from
lymph nodes in the gut, the very engine
room of inflammatory bowel disease.
Shilling first devised a new technique 
to purify dendritic cells to 95% purity,
significantly better than the 50%
achieved with previous techniques. 
This allowed them to discover that, 
if dendritic cells from the gut are
presented with probiotic bacteria, 
they will stimulate a positive immune
response that protects the bowel from
inflammation. This promising finding
suggests probiotics might one day 
help to calm inflammatory bowel
disease and possibly reduce patient
need to use steroids and anti-
inflammatory drugs.
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The key to infant
meningitis?
How do bacteria reach the
brain and cause meningitis?
Microbiologists at TCD have
discovered that reactions in 
a baby’s gut play a key role
Bacterial meningitis is a sporadic 
but potentially deadly infection that
develops when bacteria infect the
membrane, or meninges, that surrounds
the brain. Children and infants are most
at risk, and in newborn babies the main
cause is the common gut bacterium,
Escherichia coli. Some scientists think
that the E. coli start by sticking to 
the epithelial cells lining the gut, then
somehow burrow through, reaching 
the blood stream which then fast-tracks
the bacteria to the brain. TCD
microbiologists Dr Stephen Smith 
and PhD student Robert Fagan are
investigating this, by studying how 
the bacteria stick to the gut cells.
The outer surface of E. coli bacteria 
is covered with a variety of adhesin
molecules, and Smith and Fagan
discovered that several of these can
stick to human gut cells. What is more,
when they produced E. coli with no
adhesins, and tested these in the
laboratory, the mutant bacteria could
not stick to, or burrow through, human
gut cells. Clearly, adhesins are crucial,
and it seems that each adhesin has 
a particular shape that engages with 
a matching molecule on the surface of
the human cell, just as a key fits a lock.
Smith and Fagan discovered that one
of their keys, which they called Hek,
attaches directly to a complex
proteoglycan molecule on human gut
cells. To confirm this, they engineered
gut cells in the laboratory that cannot
produce proteoglycan and, sure
enough, the E. coli could not attach 
and attack them. Detailed information
such as this may one day help
scientists to design new antibiotics.
How to avoid
cancer of the
oesophagus
Smoking and being
overweight makes some
people more prone to
developing oesophageal
cancer, a national cancer
study reveals
Eat more fruit and less fat, lose weight
and stop smoking. It’s good advice for
all of us, but especially for people 
with a condition known as Barrett’s
oesophagus. In this disease, thought 
to be caused by acid reflux from the
stomach, the lining of the oesophagus
changes, becoming more rough and
resembling the intestine. And people
with Barrett’s oesophagus who are
overweight and who smoke, are more
at risk of developing a nasty cancer 
of the oesophagus called
adenocarcinoma. That’s the finding
from an all-Ireland study of nearly 750
people, one-third of whom were
healthy, one-third had Barrett’s
oesophagus, and one-third
adenocarcinoma. The incidence of
adenocarcinoma has doubled in 10
years, and it now accounts for half of
oesophageal cancers in Western
societies. This is worrying, because 
the survival rate is low: at most 12% 
of patients survive to five years. People
with Barrett’s oesophagus are 20 times
more at risk, although it must be
stressed that most people with Barrett’s
oesophagus do not develop cancer. 
Using data collected from patients
around Ireland, Dr Harry Comber and
Ms Siobhan Reynolds, of the National
Cancer Registry, Cork, in collaboration
with the Northern Ireland Cancer
Registry, found that the people most
likely to develop adenocarcinoma are
those with Barrett’s oesophagus who
are also overweight and smoke. 
These patients should therefore be
encouraged to lose weight and stop
smoking. While there is much debate
about whether people with Barrett’s
oesophagus should have regular
endoscopy examinations, the results 
of this study suggest it would be
particularly useful for overweight
patients.
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How mimics can
turn your body
against you
If a bug starts to mimic the
cells in your stomach you
could end up with stomach
cancer, microbiologists at
NUI Galway have discovered
Bacteria are wonderful mimics. 
To evade the clutches of your immune
system many have evolved surface
molecules similar or even identical 
to structures normally found on the
surface of your own cells, which often
fools the immune system into not
recognising the invader. But if the
infection continues for a long time, 
the immune system may eventually
wise up and produce antibodies against
the bacteria. Unfortunately, these
antibodies will also recognise the
original structures the mimics were
copying. The result is an autoimmune 
disease, when the body’s immune
system turns against itself.
Now, researchers at NUI Galway, 
led by Dr Anthony Moran, have
discovered that this happens with 
some strains of Helicobacter pylori. 
This common bacterium causes peptic
ulcers and an inflammation of the
stomach lining called gastritis. In severe
cases, the acid-secreting cells in the
stomach are destroyed (a condition
called atrophy), which can be a prelude
to stomach cancer. Moran and
colleagues have discovered that the 
H. pylori strains associated with atrophy
carry molecules identical to the Lewis
antigens normally found on the
stomach’s acid-producing cells.
Significantly, they found that antibodies
produced against these bacteria will
also recognise the acid-producing 
cells, confirming that a major cause 
of the atrophy is probably the immune
system turning against the stomach
cells and starting to destroy them. 
The researchers hope to develop a
quick test to determine if someone has
been infected with one of the problem
H. pylori strains. Unfortunately, once 
the auto-immune reaction has begun,
there is currently no way to stop it, so
affected people need to be monitored
for any early signs of stomach cancer.
Filming bugs –
and why they’re
so resilient 
Research at UCC into how
bacterial communities
function, could one day lead
to new antibiotics
Pseudomonas aeruginosa is a
bacterium that makes films. Not motion
pictures, but densely populated
colonies that grow as a coating 
or ‘biofilm’ on suitable surfaces,
everything from plastic tubing to the
lining of the lung. P. aeruginosa is also 
a major worry for health services.
Among other things, it causes chronic
and potentially deadly lung infections 
in people who have cystic fibrosis. Its
biofilms have a mucus-like coating that
protects the bacteria from disinfectants
and from a person’s immune system,
and this is partly what makes an
infection so difficult to treat. But
biofilms are also actively organised: 
the bacteria can sense the presence 
of their neighbours, and secrete signal
molecules to orchestrate the colony
and make it more virulent. So
researchers now study how biofilms
behave, hoping to spot chinks in 
their armour.
Within a biofilm, the bugs need iron 
to survive, but this element is difficult 
to obtain from the environment, so the
bacteria have evolved complex
mechanisms for iron uptake involving,
among other things, TonB proteins. 
At UCC’s BIOMERIT research centre,
microbiologists Prof Fergal O’Gara and
Dr Abdelhamid Abbas have discovered
a new role for TonB: they found that it is
also involved in the signalling that helps
the bugs become virulent. TonB is
active, regardless of how much iron is
present, and it helps to co-ordinate
biofilm formation and to make the
bacteria resistant to heat and other
stresses. This is a new and central role
for TonB, and understanding it could
one day lead to improved treatments
for P. aeruginosa infection.
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Filming bacteria
– what makes
them stick? 
Microbiologists at the Royal
College of Surgeons in
Ireland are studying a gene
that helps some infectious
bacteria stick to surfaces
You probably have some
staphylococcal bacteria on your hands.
Both Staphylococcus aureus and 
S. epidermidis are common in the
environment (the latter occurs on 
the skin, for instance) and both can
form biofilm communities on surfaces.
If this happens inside your body, e.g. 
in the lung, or on a medical device such
as an intravenous tube, it can cause 
a troublesome infection that is difficult
to treat, especially if it is the notorious
methicillin resistant Staphylococcus
aureus, alias MRSA. 
But what turns an everyday bug into 
a resilient biofilm? Clinical
microbiologist Dr Fidelma Fitzpatrick,
working with Dr James O'Gara and 
Prof Hilary Humphreys at the Royal
College of Surgeons in Ireland, studied
one suspect gene: the intra-cellular
adhesin (ica) gene, which controls
production of the sticky mucus that
protects a biofilm and helps it stick 
to silicone, the main constituent of
medical tubes and shunts. Analysing
samples collected from intensive care
patients, Fitzpatrick found that the two
staphylococcal species have different
biofilm mechanisms. In general, 
S. epidermidis needs ica to form a
biofilm, although, a few bacteria lacking
the gene could still form a biofilm. 
S. aureus, however, can form biofilms
whether or not they have the ica gene,
suggesting that, for them, there are
other genes that also control this
behaviour. Significantly, the biofilm
communities of MRSA and methicillin
sensitive S. aureus (MSSA), react
differently to environmental factors 
such as salt concentration, and a new
HRB-funded project is studying these
differences. The ultimate aim of the
research is to devise new and effective
ways of diagnosing and treating these
important biofilm infections.
MRSA stands for Methicillin-
Resistant Staphylococcus aureus.
MRSA is a subgroup of Staph 
aureus that is resistant to a range 
of antibiotics, including penicillin
antibiotics. MRSA first appeared 
in 1961 soon after the introduction 
of the antibiotic methicillin (an
antibiotic that is no longer in use).
Since then MRSA has spread widely
in many countries and has been
particularly associated with hospitals
and other healthcare facilities. 
Who is most at risk of getting an
MRSA infection?
In general MRSA infections tend 
to occur in older hospital patients
and those with the most severe
underlying illnesses. The following
are considered to be important risk
factors for invasive MRSA infection: 
· Age (older age groups are 
more prone) 
· Gender (males are twice-more 
at risk than females) 
· Prolonged hospital stay 
· Patients in intensive care, 
surgical and burns units 
· Patients with diabetes and other 
chronic conditions 
· Patients treated with broad-
spectrum antibiotics 
What is the best way to control 
the spread of MRSA?
The most important infection control
measure and the easiest way to help
prevent MRSA from spreading within
the hospital (and by extension in 
the community) is to foster strict
adherence to hand-washing policies
and other hygienic practices for 
all staff and visitors. 
How common is Staph aureus/
MRSA infection in Ireland?
The proportion of Staph aureus
isolates that were MRSA for the 
first nine months of 2004 was
approximately 42.4%. However,
MRSA is a global concern and not
just an Irish problem. In Europe,
apart from Ireland, the highest rates
(proportions) of MRSA bacteraemia
are observed in countries such as
Belgium (29.5%), France (28.9%),
Greece (44.7%), Italy (37.6%),
Portugal (45.5%) and the UK
(43.1%). The lowest rates
(proportions) are observed in 
Estonia, Scandinavia and the
Netherlands (all <5%).
Source: The National Disease Surveillance Centre
What is MRSA?

THE HEALTH
RESEARCH SYSTEM
IS THE BRAINS OF
THE HEALTH SYSTEM: 
IT IS A TOOL TO
ORGANISE, 
UNDERSTAND,
OPERATE AND
IMPROVE IT.
Health services: 
From the cradle to the grave
“The health research system is the
brains of the health system: 
it is a tool to organise, 
understand, operate and improve it.”  
Source: World Report on Knowledge for Better Health, WHO 2004
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Cultural diversity
and maternity
services
Interpreters and anti-racism
training are among the
changes needed if maternity
hospitals are to serve
Ireland’s new ethnic
communities, a major UCD
study recommends
Cultural diversity poses new challenges
for the health services, with over 100
ethnic communities now settling 
in Ireland. This diversity can pose
particular challenges for the maternity
services. UCD public health expert 
Dr Anna Clarke and PhD student Suzi
Lyons surveyed and compared the
experiences of 1,000 women, half from
ethnic minorities, and half Irish women
chosen to match the ethnic women 
for age and other factors, and they
interviewed health professionals 
at Dublin’s three public maternity
hospitals.
They found few differences between 
the Irish and ethnic minority women,
although the latter were less likely 
to smoke, drink alcohol or take illegal
drugs. But their study did reveal some
problems relating to the maternity
services: ethnic minority women often
presented at the hospital late in their
pregnancy and thus had fewer
antenatal visits, for instance; they were
also less likely to have had the rubella
vaccine and more likely to be anaemic,
possibly reflecting health services 
in their home country. Language
difficulties were also a problem, both
for the women and for hospital staff. 
Clarke and Lyons recommend a review
of antenatal and maternity services, 
and suggest a number of practical
measures that might be implemented
relatively quickly. Health boards could
employ link-workers from the ethnic
minorities who could act, independent
of the hospitals, as advocates and
interpreters for the women. Staff at the
maternity hospitals should also receive
cultural competency and anti-racism
training, while the antenatal care should
be tailored to the individual needs of
the women attending the clinics. 
How to divide
the health
funding pie
It would be fairer to allocate
health funding according to
needs, say analysts at TCD
Deciding how much money health
authorities should receive is an
important but difficult task. Usually,
they receive more or less what they 
got the previous year, plus a little extra
for inflation. But that might not reflect
the needs of their constituency: rural
areas need more money for geriatric
care, for instance, than towns with 
a younger population. So, increasingly
countries are switching to a ‘needs
based’ allocation of funds. Sweden
already does this, and Britain to 
a lesser extent. Health system analyst 
Dr Rosalyn O'Loughlin, working with 
Dr Alan Kelly at TCD, asked whether
needs-based funding was doable 
and desirable here.
Such a switch ideally calls for a national
database with a unique number for
each person which would allow their
health needs to be tracked and
predicted (and indeed PPS numbers 
are now being allocated to infants at
birth), plus a geographic identifier such
as a postcode. This type of database
does not yet exist here, so O’Loughlin
tested her ideas on estimated data and
found that, had she been in charge of
funding, the Eastern, Southern and
Midwestern health boards would have
received less money (down 4.4%, 0.6%
and 0.4% respectively), and the five
other health boards more, with 1.8%
more for the Western health board. 
The readjustments seem small, but 
the sums involved are substantial.
Interestingly, the results confirms 
a widely held view that the eastern
region is over-funded and the west
under-funded. 
O’Loughlin and Kelly have presented
their ideas to the new Health Services
Executive, and believe their system
could be implemented within 5-10
years. And fairer health funding would
be a positive incentive to introduce
individual ID numbers and postcodes.
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A rational way 
to plan health
services
People living in border
counties should have access
to hospitals across the
border, a TCD study of health
facilities recommends
How far would you travel for a GP?
What about specialist cancer care?
Public health researchers at TCD 
have been analysing how far people
currently travel to access health care,
using data from across the country. 
Not surprisingly, they found that in
general, the more specialised the care,
and the less widely available the
service, the more people are prepared
to travel and the longer their journey.
The research team of three – Dr Alan
Kelly and PhD student Conor Teljeur
and researcher Imanol Montoya – then
wrote software to plan the optimum 
locations for health care facilities, taking
into account existing services. 
Overall, they found that existing
facilities are reasonably well located –
for instance, while counties Carlow,
Longford and Leitrim have no hospital,
residents there are no worse off on
average than those living in other
similar regions. That said, people living
in Leitrim, north Cavan, Donegal and
Monaghan would have quicker hospital
access if they could use facilities
across the border. The converse holds
true for residents in adjacent NI
counties and the researchers
recommend abolishing this ‘health care
border’. The team also considered the
optimum locations for new primary
health care centres, the ‘one-stop
shops’ intended to replace between
one-third and two-thirds of 
GP surgeries. Co Kildare currently has
35 GP surgeries, and the researchers
found that these are well-placed to
serve the population. Their analysis
recommends 33 primary health care
centres for the county, a drop of just
two, and in essentially the same
locations as the existing surgeries.
Having proved their system with this
case study, the team believes it is 
a valuable practical tool that should 
be used when planning changes to 
the health services.
The new face 
of after-hours
GP care
Out-of-hours co-operatives
and locally-based
defibrillators can help in
providing emergency medical
care, a UCD survey reveals*
Gone are the days when a GP could
single-handedly offer after-hours care
round the clock, and the trend now 
is towards co-operatives that share 
the burden. They first began in 1998,
and today 11 co-ops across the
country provide cover for over 1,000
GPs (about 40% of the total), and offer
care to some 1.5 million people. 
The co-ops run what are effectively
medical call centres, staffed by triage
nurses and GPs who can deal with
many queries over the phone. 
To analyse how this change in care 
is operating, UCD’s Professor of
General Practice, Dr Gerard Bury 
and colleagues surveyed all 11 co-ops,
with a special focus on how they
manage emergencies. Their survey
reveals that, in one recent year, the 
co-ops handled 340,000 calls from
patients; 32% of the queries were dealt
with over the phone, 56% were referred
for consultation at a treatment centre,
and just 12% led to a doctor making 
a house call. Significantly, because 
the co-ops see their role as preparing
for emergencies that arise in normal 
GP care, rather than as a dedicated
emergency service, they have few
formal links with the ambulance
services, something Bury is studying 
in a follow-up survey. 
The project also analysed the availability
and use of community-based portable
defibrillators, such as the County
Wicklow scheme, where community
groups were given defibrillators and the
local ambulance service has a contact
list for volunteers on-call. This meant
that in one recent emergency, a
volunteer reached the victim within three
minutes, and 20 minutes before the
ambulance arrived.  However, the UCD
survey could not trace most of the
portable defibrillators sold here, and
recommends a registration system to
improve access to the devices.
*This study was co-funded by the 
Pre-Hospital Emergency Care Council
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I spy with my 
X-ray image
An Irish study of hospitals 
in four countries found that 
X-ray image quality varies
significantly, and
recommends continuous
training for staff and the
publication of a set of
reference images
X-ray images are used to diagnose
injuries and illness, and so image quality
must be high, with good contrast 
and resolution, and showing all 
the necessary anatomical detail. 
A radiologist needs to be able to see
clearly not just the hip joint, for instance,
but also the bony patterns within it.
There are, however, few practical
guidelines for image quality, and most
recent emphasis has been on minimising
the X-ray dose the patient receives.
While this is important, it is also vital that
image quality does not suffer as a result.  
To investigate whether quality varies
from hospital to hospital, Dr Patrick
Brennan, from UCD’s School of
Diagnostic Imaging, and PhD student
Ebtehal Al-Qattan, analysed some
5,000 images taken in 20 hospitals
across four countries – Ireland, the UK,
Kuwait and Oman – the first time such
a comprehensive study has been done
for anatomical X-rays (previous studies
focused on dental images). They
devised a new scoring system that
allowed them to rate image quality 
and to determine if loss of quality 
was due to the equipment used or 
the technique.  Significantly, they
concluded that equipment and
techniques are not always up to
standard, and that new digital imaging,
while more convenient than film, does
not necessarily produce better images.
Brennan and Al-Qattan recommend
publishing sets of reference images, 
so X-ray departments are reminded 
of what an image should be like, and
running refresher training courses. 
The study findings have been presented
internationally, and researchers and
clinicians in Northern Ireland and the
Irish Republic are now reviewing how
best to improve their clinical practice.
Death, dying
and dementia
How can we best meet 
the special end-of-life care
needs of people with
dementia? A Dublin
sociological study has 
some practical suggestions
Palliative care is a valuable service 
for cancer patients and their families,
and one that should be more widely
available. The service grew out of
cancer care, but that model won’t suit
all patients: people with dementia, 
for instance, have special needs, as 
by the time they require end-of-life
care, their cognitive abilities are often
severely limited, making it hard for staff
to assess symptoms and pain levels. 
To explore what might be done to help
dementia patients and their families,
sociologist Dr Una MacConville, in
association with consultants Regina
McQuillan (St Francis Hospice) and 
Dr Mary Cosgrave (St Ita’s, Portrane),
interviewed bereaved family members,
and professionals working in palliative
and dementia care. 
MacConville found that dementia
services could usefully include families
more in the care, especially as many
families, having cared for their relative
for a long time, will have a deep
knowledge of the person with
dementia. Also, families can find 
the move to institutional care and 
the change from being the main carer
difficult.  Resources emerged as 
a major issue, and a shortage of
appropriately trained staff means
dementia care institutions cannot
provide the full range of end-of-life
support services for patients and 
their families. So a first step might be 
a partnership scheme, as proposed 
in Britain, allowing palliative and
dementia care professionals to share
their expertise. Both dementia care staff
and palliative care professionals would
benefit: dementia care professionals
have specialist knowledge of caring 
for people with dementia and palliative
care professionals have specialist
knowledge of end-of-life care. 
NOW IS THE TIME
TO MAKE IT
HAPPEN WHERE IT
MATTERS, BY
TURNING
SCIENTIFIC
KNOWLEDGE INTO
EFFECTIVE ACTION
Human disease:
Confronting the causes
“Now is the time to make it happen
where it matters, by turning
scientific knowledge into effective
action for people’s health.”  
Source: World Report on Knowledge for Better Health, WHO 2004
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Stopping 
the push of
premature labour
Obstetricians at NUI Galway
have discovered a new drug
that may be able to stop 
the muscle contractions of
premature labour, and with
fewer side-effects than the
drugs currently used to treat
this life-threatening problem
If a pregnant woman goes into labour
before her allotted nine months, and
particularly before 7-8 months, it can
lead to major problems, as babies born
prematurely need special care and are
at risk of developing physical or
intellectual handicap. Even then many
premature infants do not survive, while
those that do survive are often prone 
to long-term health problems. These
premature births usually happen when,
for reasons that are not yet understood,
muscles in the womb start contracting
before the due date. To save the
pregnancy, drugs such as ritodrine 
have been prescribed to stop the
contractions, but these can have
serious side effects, notably on the
blood pressure of both mother and
baby and their use is now discontinued.
Now, obstetrician Prof John Morrison
and PhD student Paul Hynes, at NUI
Galway, have discovered a promising
new drug that could have fewer side
effects. In laboratory tests, the
compound (currently known only as
BRL 37344), is as good as, if not better
than ritodrine in stopping the muscle
contractions. Significantly, however, 
it has less effect on blood vessels,
suggesting it is less likely to cause
blood pressure problems. 
The Galway team has discovered that
the new drug acts on a protein called
beta-3 adrenoreceptor, which is
involved in relaxing and contracting 
the muscles of the womb. To date, 
they have tested the drug only on
muscle samples and blood vessels 
in the laboratory, and more research 
is needed before BRL 37344 could
proceed to clinical trials. But these
initial results suggest that this could 
be a promising new treatment for what
is currently a very serious and
distressing problem.
Understanding
pre-eclampsia –
our constricted
knowledge
Why do blood vessels
sometimes constrict and
malfunction in pregnancy?
Obstetricians at NUI Galway
are piecing together what
happens
Pre-eclampsia is relatively common 
in pregnancy, with symptoms that
include high blood pressure and
swelling in the mother. Fortunately,
most cases are mild, but in severe
cases, the baby might be born small 
or must be delivered prematurely, 
and sometimes the problem can even
threaten the mother’s life. The condition
develops when the blood vessels in the
womb, and in the placental circulation
supplying the baby, contract too much
and become constricted, but it’s not
known what causes this. Somewhat
more is known about normal high blood
pressure, or hypertension, in people
who are not pregnant. In particular, 
constricted blood vessels in such cases
are associated with what biochemists
refer to as the Rho A/Rho-kinase
system, involving a small signalling
molecule, Rho A, and an enzyme, 
Rho-kinase. NUI Galway obstetrician,
Prof John Morrison, and Dr Anne 
M Friel, wondered if the same system
played any role in pre-eclampsia.
They discovered that the genes for 
the Rho A system are actually less
active in blood vessels constricted 
by pre-eclampsia, something they
could determine by measuring the
amount of mRNA the genes produced.
This suggests that the constrictions in
pre-eclampsia are not triggered by the
same factors as in normal hypertension.
The reason Rho A levels are down in
pre-eclampsia, the researchers think, 
is because the mother’s body is trying
to compensate for the poor blood
supply by reducing the amount of 
Rho A circulating, in the hope that this
will relax the blood vessels and not 
add to the problem.
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Arthritis and 
a two-faced
hormone
An anti-inflammatory
hormone that actually
provokes inflammation 
in arthritis? Biochemists 
at UCD have uncovered 
a hormonal puzzle
If one of your joints starts to become
arthritic, then the thin synovium that
lines the joint changes dramatically.
New blood vessels grow and the cells
proliferate, so that the synovium
thickens into a tumour-like growth.
Hormones are thought to play a role in
these changes, not least because most
arthritic diseases are more common
among women than men. At UCD, 
cell biologist Dr Evelyn Murphy and
PhD student Jennifer Ralph study 
one hormone, corticotropin-releasing
hormone (CRH), which is part of our
‘fight or flight’ stress response. 
They built a cell culture system in their
laboratory where they can monitor 
how cells respond to CRH.
Normally, CRH binds to receptors on
the surface of cells, and this starts a
chain reaction that eventually triggers
the adrenal glands to produce the
body’s natural steroids. In this way,
CRH acts as an anti-inflammatory
hormone. Ordinarily, no CRH receptors
are found in synovial tissue, but the
UCD team discovered that the
receptors are present in arthritic joints.
With their cell culture system, they
found that adding CRH to arthritic
synovial tissue made it leaky, in a way
that would allow immune cells to move
into the tissue from the blood system.
In other words, in an arthritic joint, CRH
may actually provoke inflammation. 
This two-faced behaviour is not
unusual, and several other molecules
can act in opposite ways depending on
the situation. The discovery of CRH’s
role in arthritic inflammation opens a
new avenue to explore for an effective
treatment of arthritis.
Could calcium-
control drugs
alleviate muscular
dystrophy?
Muscle biologists at NUI
Maynooth found that calcium
regulation is important in
muscular dystrophy, pointing
the way to a possible therapy
Muscular dystrophies are crippling
neuromuscular diseases, mostly caused
by a defect in the gene that codes for
the dystrophin protein. The gene lies on
the X chromosome so, like haemophilia,
this is a disease that only boys develop,
and it affects about one in every 3,000
boys born in Ireland. Their muscles
quickly degenerate and most will die
before they reach 30, when their heart
or respiratory muscles fail. Dystrophin
protein sits on the muscle cell surface,
connecting the inside and outside of
the cell. Some forms of the disease are
more severe than others, depending on
whether the person has no dystrophin
at all, or not enough, or a faulty type of
protein. The net result in all cases,
however, is inflexible muscle cells that
eventually rupture, allowing calcium
ions to flood in, and eventually leading
to muscle degeneration.
Now, Prof Kay Ohlendieck and PhD
student James Lohan have discovered
other proteins that are involved. Using
new proteomic techniques, they can
take snapshots that show which
proteins are active in a cell. Comparing
snapshots for healthy and diseased
muscle and heart muscle cells revealed
that levels of two proteins involved in
calcium ion regulation drop significantly
in diseased muscle cells. For
Ohlendieck, this suggests that certain
drugs, already used to control calcium
levels in other diseases, might help to
alleviate some of muscular dystrophy’s
distressing and severe symptoms.
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A more humane
way to test
toxins
A type of artificial kidney 
built at UCD, is shedding 
light on how kidney damage
develops, and could be 
used instead of animals 
to test poisons*
Cell biologists at UCD’s Conway
Institute have made an artificial kidney
by successfully growing two types of
human kidney cell on filters in the
laboratory. It doesn’t look like a kidney,
and it isn’t a replacement for kidney
transplants, but it is a reasonable
mimic, capable of filtering and
reabsorbing fluids, and already it is
allowing Prof Michael Ryan and his
team to investigate how drugs and
toxins affect kidney cells and how
kidney disease develops. 
The aim is to find an alternative to
animal testing – currently, millions of 
lab animals are killed each year in
toxicity tests. Cell cultures are an
attractive solution, and would also 
allow scientists to study how toxins
cause kidney damage, but the
stumbling block has been creating 
cell cultures that realistically mimic 
the human kidney.
Ryan and his colleagues believe they
have now done this, and the proof
comes in their studies of the immune
suppressant drug, cyclosporin A, which
can cause serious kidney damage.
Using their artificial kidney, Ryan’s team
has shown that, although cyclosporin 
A suppresses most immune functions,
it does stimulate kidney cells to
produce a particular immune molecule,
called transforming growth factor beta,
which provokes inflammation and
damages the cells. The team has also
seen how certain cells in their kidney
culture can transform and become
diseased, and as well as shedding light
on how disease develops, this confirms
the value of their artificial system. 
The team has published its findings
internationally, and hopes that their
ongoing work on cyclosporin A might
lead to safer immune suppressant
drugs.
*Co-funded by the Hadwyn Trust for
Humane Research
Live action replay
– for pathologists!
Sophisticated new software
from DCU can record and
replay how a pathologist
views a microscope slide,
and is revolutionising
pathology training and 
quality assurance
Diagnostic pathology is a complex
process requiring many years of
postgraduate training to achieve
suitable standards of performance.
Decision-making is not clear-cut and
requires pathologists to weigh up
several features before coming to any
decision. This process of educating
trainees is complicated by the fact that
most training is performed via a
conventional microscope, a labour
intensive process that requires the
expert pathologist to sit with the trainee
pathologist at a double headed
microscope for sustained periods 
of time.
All that is now changing, thanks to
software developed at DCU by Dr
Donal O’Shea and PhD student Dan
Johnston. Their ReplaySuite program
exploits the power of digital
microscopy, which can capture the
detail of microscopic samples at
suitable resolution for diagnosis. Their
system tracks where a pathologist visits
as they view a digital slide, and can
then replay this to others, whether
trainee pathologists or for quality
assurance assessment. And the beauty
of the digital system means replays can
be reviewed anywhere in the world.
The DCU approach is now being
adopted by companies selling digital
pathology slide systems, and a spin-off
company at DCU, Slidepath, is
marketing a range of related services.
Already, a quality assurance study they
have undertaken in Sweden, on the
diagnosis of chronic hepatitis in liver
biopsies, revealed that some people
were not viewing enough of the slide, 
or using too low a magnification to
come to an appropriate conclusion.
Slidepath also plans to offer master
classes with world experts, which
O’Shea likens to ‘pay-per-view’ training
courses for pathologists. So, simply by
tracking where a pathologist looks, an
elegant Irish idea is helping to improve
the quality of medical diagnoses.
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A new way to
tackle psoriasis
A tried and tested anti-
inflammatory drug is also
effective against psoriasis, 
a trial at St Vincent’s
University Hospital has found
The drug Infliximab is licensed for use
in treating certain inflammatory
disorders, such as rheumatoid arthritis
and inflammatory bowel disease. 
It works by blocking a protein called
TNF-α, which normally triggers the
inflammation that is a feature of these
diseases. But inflammation is also 
a feature of psoriasis – so, might
Infliximab be effective against this
condition too? 
Psoriasis is characterised by red scaly
patches on the skin, and inflamed
joints. Both are associated with new
blood vessels forming, a process which
is regulated by various growth factors,
including vascular endothelial growth
factor (VEGF) and angiopoietins 1 and
2. At St Vincent’s University Hospital 
in Dublin, dermatologist Dr Trevor
Markham, working with Dr Douglas
Veale, conducted a clinical trial of
Infliximab with psoriasis patients, and
he also investigated the drug’s effects
on growth factors in the laboratory.
Markham found that Infliximab 
was very effective against psoriasis,
dramatically reducing the patients’ skin
and joint problems. Patients taking 
the drug had less of the VEFG and 
the angiopoietins in their blood,
suggesting these growth factors are
important in psoriasis. Experiments 
on skin cells in the laboratory confirmed
that VEFG and the angiopoietins do
stimulate inflammation and new blood
vessel formation. On the down-side,
Infliximab is time-consuming to
administer (it requires a two-hour
intravenous drip), and there are
concerns about long-term side-effects.
Yet, it was so effective it’s likely to be
used to treat some patients, and
already, new improved derivatives are
being developed to block TNF-α, 
and this important study proves that
these drugs should be effective 
against psoriasis. 
Ironing out the
problems of
haemachromatosis
Severe bloodletting, the
conventional treatment for
hereditary haemochromatosis,
may not be as appropriate 
as previously thought,
research at Dublin’s Mater
Hospital suggests
Fatigue, joint pain and, occasionally 
in men, impotence. These are the 
early symptoms of hereditary
haemachromatosis, a common genetic
disorder that develops if your body
absorbs too much iron from the diet.
The excess iron is deposited primarily
in the liver and can lead to cirrhosis 
of the liver and, in rare circumstances,
liver cancer. Early diagnosis is
important and if treatment starts 
in time, it can restore the person’s
normal life expectancy, although the
conventional treatment seems medieval
– weekly bloodletting (phlebotomy) to
remove the excess iron. Some experts
now think this exacerbates the problem
– because forcing the body to replace
lost blood may increase the rate at
which iron is absorbed from the diet.
Clearly, there is much we do not
understand about this disease,
although recent genetic studies have
helpfully identified several genes and
proteins involved in iron metabolism. 
At the Centre for Liver Disease in
Dublin’s Mater Hospital, molecular
biologist Dr Eleanor Ryan and PhD
student Barry Kelleher studied biopsy
samples donated by haemachromatosis
patients before and after phlebotomy,
to see which genes and proteins are
activated.  They found that bloodletting
does raise the levels of a key protein,
DMT1, involved in absorbing iron from
food in the duodenum. This suggests 
it might be wise to take less blood, 
less often.  The team is now studying 
a protein called hepcidin, which is
involved in switching iron absorption 
on and off, and hope to develop a test
to measure blood  hepcidin levels.
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